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Human Immunodeficiency Virus Type 1 (HIV) replication, by building upon a previous CD4-based CAR
that was employed in several clinical trials. We applied lessons learned from cancer-targeting CARs to
optimize the CAR vector backbone, promoter, HIV targeting moiety, and transmembrane and signaling
domains, in an effort to determine which components augmented the ability of CD8 T cells to control HIV
replication. CD8 T cells expressing the optimized CARs were at least 50-fold more potent in vitro at
controlling HIV replication than the original CD4 CAR or TCR-based approaches and substantially better
than broadly neutralizing antibody-based CARs. We then utilized a humanized mouse model of HIV infection
to demonstrate superior control over HIV replication, better protection of CD4 T cells, and greater CAR T
cell expansion with the optimized vectors compared to the original clinical trial vector. Compared to
optimized CD4 CARs containing the CD28 costimulatory domain, CARs containing 4-1BB expanded better
in vivo in the absence of antigen and resulted in greater control over HIV replication. We found that the CD4
CAR promoted infection of transduced CD8 T cells and employed CCR5 zinc finger nucleases (ZFNs) or a
GP41-based fusion inhibitor to protect the CAR T cells. We employed ZFN-pretreated, CAR-transduced
CD8 T cells in our mouse models and saw an enrichment of the disrupted alleles in HIV-infected mice
compared to mock controls. In humans, a functional cure will require CAR T cells to prevent the spread of
HIV following virus reactivation from the latent reservoir. We modeled this scenario in vitro using ART
patient T cells and latency reversing agents (LRAs). Preliminary data suggest that CD4 CAR T cells can
respond to low levels of antigen produced by resting ART patient cells in the presence of LRAs. Together,
these data indicate that potent HIV-specific T cells can be generated using improved CAR design and provide
optimism that CAR T cells could help achieve a functional cure.
Degree Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Graduate Group
Cell & Molecular Biology
First Advisor
James L. Riley
Keywords
adoptive T cell therapy, chimeric antigen receptor, HIV-1
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2419
Subject Categories
Allergy and Immunology | Immunology and Infectious Disease | Medical Immunology | Microbiology |
Virology
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2419
ENGINEERING CHIMERIC ANTIGEN RECEPTORS FOR DURABLE  
CONTROL OVER HIV-1 REPLICATION 
Rachel Shira Leibman 
A DISSERTATION 
in Cell and Molecular Biology 
Presented to the Faculties of the University of Pennsylvania 
In Partial Fulfillment of the Requirements for the 
Degree of Doctor of Philosophy 
2017 
Supervisor of Dissertation      
_________________________________      
James L. Riley, Ph.D. 
Research Associate Professor of Microbiology 
 
Graduate Group Chairperson 
____________________________________ 
Daniel S. Kessler, Ph.D. 
 Associate Professor of Cell and Developmental Biology 
 
Dissertation Committee 
 
Rahul M. Kohli (Chair), M.D., Ph.D., Assistant Professor of Medicine 
E. John Wherry, Ph.D., Richard and Barbara Schiffrin President's Distinguished 
Professor 
James A. Hoxie, M.D., Ph.D., Professor of Medicine 
Robert H. Vonderheide, M.D., Ph.D., Hanna Wise Professor in Cancer Research 
ii 
 
ACKNOWLEDGMENTS 
 
First and foremost, I would like to thank my advisor Jim.  His intelligence 
and breadth of knowledge constantly amaze me.  His creativity and experimental 
acuity has helped foster a laboratory environment filled with many exciting 
projects.  I could not have been this successful in my thesis work without such a 
helpful and supportive mentor, and I have become a stronger and more 
passionate scientist because of Jim’s training. 
Additionally I would like to thank all of the Riley lab members, both present 
and past, for their important contributions to my project and my well-being while 
in the lab.  In addition to experimental advice and assistance, the lab is filled with 
amazing people who make the long work days enjoyable.  I respect and admire 
each one of you very much.  Colby Maldini was a life-saver and helped me with 
an extra set of hands for experiments, data discussions, and FlowJo assistance 
on many occasions.  A nicer, more helpful labmate does not exist!  I have Chris 
Ecker to thank for understanding (the tip of the iceberg of) metabolism.  Your 
light-hearted personality brightens up the lab and makes people laugh, and I 
have enjoyed our rock-climbing and skiing adventures.  Gavin Ellis, Jan Pawlicki, 
and Kevin Tosh are all wonderful, dedicated, and helpful post-docs who are each 
instrumental in making the Riley lab an exciting and fun place to work.  Max 
Richardson is invaluable for his breadth of knowledge and ability to read data 
(and between the lines of other peoples’ data!).  Max’s help was critical to this 
project’s success.  Hong Kong has been an amazing and kind lab manager, and 
iii 
 
is always able to solve lab issues.  Andrew Medvec was a wonderful and patient 
mentor, Julie Jadlowsky helped teach me to work with HIV-1, and Sarah Gwyn 
was an amazing labmate and friend.  Chui Lau and Emily Winters were 
extremely helpful getting fresh donor cells each week as well. 
I would like to thank my committee members: Dr. Rahul Kohli, Dr. John 
Wherry, Dr. Jim Hoxie, and Dr. Bob Vonderheide for their valuable feedback and 
project guidance over the past few years.  Your dedication to high quality science 
is what makes Penn one of the top research universities in the country.   
I would also like to thank Dr. Una O’Doherty for her collaboration on 
reservoir studies including members of her lab Erin Graf, Matt Pace, and Jake 
VanBelzen; Dr. Aimee Payne and Dr. Christoph Ellebrecht for their guidance and 
help on the scFv CAR experiments; and all of the labs, cores (HIC, CFAR, 
SCXC, etc.), administrative staff, and industry collaborators that have helped 
make this project, and my entire graduate school experience, possible.   
I would be remiss to not mention Bob Doms for his amazing mentorship 
and guidance, specifically during the first two years of my graduate degree.  
Similar thanks to the PHCP certificate mentors, Brian Keith, JA Grisso, and 
Hillary Nelson who developed a wonderful program to broaden the public health 
viewpoints of biomedical PhD candidates.  I am very appreciative of my early 
science mentorship from Dr. Brett Couch, Dr. Gary Dunny, Dr. Aaron Barnes, Dr. 
Kristi Frank, Erin Satterwhite, Dr. Jesse Miller, and Dr. Jeremy Yarwood.  I would 
also like to thank my wonderful friends, both those from childhood years and my 
iv 
 
graduate school friends from the Penn community, for all of their social and 
scientific support over the years.    
Lastly, I would like to thank my family for all their support and 
encouragement over the years, and for fostering my appreciation for learning and 
solving problems.  I have them to thank for my hard work ethic.  My mom, dad, 
brothers, grandparents, cousin Elaine, and aunt Janice and Uncle Jerry have 
been great sources of support and love over the years.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
ABSTRACT 
 
ENGINEERING CHIMERIC ANTIGEN RECEPTORS FOR DURABLE 
CONTROL OVER HIV-1 REPLICATION 
 
Rachel S. Leibman 
James L. Riley 
   
  This thesis project aimed to develop chimeric antigen receptors 
(CARs) capable of durably suppressing the Human Immunodeficiency Virus Type 
1 (HIV) replication, by building upon a previous CD4-based CAR that was 
employed in several clinical trials.  We applied lessons learned from cancer-
targeting CARs to optimize the CAR vector backbone, promoter, HIV targeting 
moiety, and transmembrane and signaling domains, in an effort to determine 
which components augmented the ability of CD8 T cells to control HIV 
replication.  CD8 T cells expressing the optimized CARs were at least 50-fold 
more potent in vitro at controlling HIV replication than the original CD4 CAR or 
TCR-based approaches and substantially better than broadly neutralizing 
antibody-based CARs.  We then utilized a humanized mouse model of HIV 
infection to demonstrate superior control over HIV replication, better protection of 
CD4 T cells, and greater CAR T cell expansion with the optimized vectors 
compared to the original clinical trial vector.  Compared to optimized CD4 CARs 
containing the CD28 costimulatory domain, CARs containing 4-1BB expanded 
better in vivo in the absence of antigen and resulted in greater control over HIV 
replication.     
vi 
 
 We found that the CD4 CAR promoted infection of transduced CD8 T cells 
and employed CCR5 zinc finger nucleases (ZFNs) or a GP41-based fusion 
inhibitor to protect the CAR T cells.   We employed ZFN-pretreated, CAR-
transduced CD8 T cells in our mouse models and saw an enrichment of the 
disrupted alleles in HIV-infected mice compared to mock controls.   
 In humans, a functional cure will require CAR T cells to prevent the spread 
of HIV following virus reactivation from the latent reservoir.  We modeled this 
scenario in vitro using ART patient T cells and latency reversing agents (LRAs).  
Preliminary data suggest that CD4 CAR T cells can respond to low levels of 
antigen produced by resting ART patient cells in the presence of LRAs.  
Together, these data indicate that potent HIV-specific T cells can be generated 
using improved CAR design and provide optimism that CAR T cells could help 
achieve a functional cure. 
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CHAPTER 1 – Introduction: Engineering T cells to Functionally Cure HIV-1 
Infection 
 
 
Parts of this chapter were previously published in: 
 
R. S. Leibman, J. L. Riley, Engineering T Cells to Functionally Cure HIV-1 
Infection. Molecular therapy : the journal of the American Society of Gene 
Therapy 23, 1149-1159 (2015). 
 
 
Overview 
 
Despite the ability of antiretroviral therapy (ART) to minimize Human 
Immunodeficiency Virus Type 1 (HIV) replication and increase the duration and 
quality of patients’ lives, the health consequences and financial burden 
associated with the lifelong treatment regimen render a permanent cure highly 
attractive.  Although T cells play an important role in controlling virus replication, 
HIV is adept at avoiding, destroying, and debilitating the naturally generated T 
cell responses (1-3).  Therefore, there is a need to develop HIV-specific T cells 
with greater potency for use in HIV cure strategies.   
Direct genetic manipulation of T cells for adoptive cellular therapies (ACT) 
could facilitate a functional cure by generating HIV-1-resitant cells, re-directing 
HIV-1-specific immune responses, or a combination of the two strategies (4).  In 
contrast to a vaccine approach, which relies on the production and priming of 
HIV-1-specific lymphocytes within a patient’s own body, adoptive T cell therapy 
provides an opportunity to customize the therapeutic T cells prior to 
administration (Fig 1-1).  However, after decades of research and advances in 
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the HIV cure and T cell immunotherapy arenas, it remains unclear how to best 
engineer T cells so that sustained control over HIV-1 replication can be achieved 
in the absence of antiretroviral therapy.   
 
Infusing more HIV-1 specific T cells fails to control HIV-1 infection 
 
Attempts to manufacture T cells as therapeutic agents to treat HIV have 
been ongoing for over two decades.  After discovering the critical role that 
cytotoxic T cells (CTLs) play in controlling HIV replication in vivo, researchers 
sought to augment the activity of natural CTLs (5-8).  When reinfusion of a single 
expanded Nef-specific CTL clone led to virus escape, it became clear that 
approaches that limited HIV escape would have to be employed, including more 
broadly targeted CTL populations (9).  Along these lines, Lieberman et al. 
expanded polyclonal HIV-specific CD8 T cells from patients by using autologous 
B-LCL lines pulsed with a mixture of Env, Gag, and Nef peptides prior to 
reinfusion.  However, the decreases in plasma and cell associated virus were 
minimal and not statistically significant at 24 weeks post infusion (10).  Similarly, 
Tan and colleagues infused two CTL clones that were rapidly eliminated upon 
reinfusion, possibly due to an over-stimulated and overly-mature Fas+/CD28- 
phenotype, exacerbated by the lack of CD4 T cell help (11).  Toxicity concerns 
then led to the incorporation of the hygromycin phosphotransferase–thymidine 
kinase (HyTK) suicide gene, which would lead to cell death in the presence of 
ganciclovir.  Riddell et al. selected Gag-specific CTLs and incorporated a 
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retrovirally-delivered HyTK suicide vector; however, this evoked a CTL response 
against the modified gene itself and elimination of infused CTLs (12).   To track 
homing and persistence, Brodie et al. retrovirally modified Gag-specific CTLs to 
express the neomycin phosphotransferase (neo) gene (13).  Although a transient 
decrease in productively infected cells in the lymph node was observed and neo-
marked CTLs were co-localized with HIV RNA+ cells in the lymph nodes, CTL 
persistence declined rapidly.  Together, these early studies highlight the difficulty 
of engineering effective, safe, and sustained HIV-specific T cell therapies. 
 
A case for gene therapy to treat HIV-1 infection  
 
With 20 plus years of additional wisdom, it is interesting to consider why 
these initial clinical trials failed to show durable control of HIV replication.  For 
one, the technology to expand T cells for adoptive T cell therapy was still in its 
nascent stage and has subsequently improved significantly, accelerated by 
success in cancer adoptive immunotherapy (14).  Initial efforts to expand single 
cells in the presence of high IL-2 levels over a period of months have evolved 
into procedures that manufacture equivalent or higher numbers of cells over a 
period of 10 days, with better engraftment potential and more robust effector 
activity.  Technological advances in vector design have optimized transgene 
expression by incorporating strong promoters, enhancer elements, nuclear 
translocation signals, and post-transcriptional regulatory elements (15-17).  
Conceptually, the field has a better understanding of the immunological 
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challenges surrounding adoptive therapy for HIV.  It is now known that the 
immune system makes a robust response to HIV infection, and HIV-specific CD8 
and CD4 T cells can be readily identified in untreated, HIV-positive individuals 
(18).  However, HIV has largely figured out how to evade the natural cell-
mediated immune response (1, 19, 20).  Thus, the rationale to infuse more HIV-
specific T cells is not as sound as the rationale to infuse better HIV-specific T 
cells.  Specifically, T cells that persist in vivo, maintain cytolytic activity, and 
target epitopes required for virus replication so that escape would be 
accompanied by a decrease in viral fitness.  Moreover, infusing billions of HIV-
specific CD8 T cells without HIV-specific CD4 T cell help is akin to deploying 
soldiers without the necessary supplies to sustain the fight.  There might be 
some short-term benefit, but it is difficult to imagine how a war might be won with 
this strategy.  Unfortunately, rapid infection and depletion of these HIV-specific 
CD4 T cells negates and complicates the benefits of infusing CD4 T cells to 
support CD8 cytolytic effector functions (3).     
 
Redirecting polyclonal T cells to target HIV-1   
 
Once the propensity for CTL-induced virus escape was established in the 
early adoptive therapy trials, researchers next sought to improve upon the natural 
cell-mediated cytotoxic responses by engineering artificial antigen receptors.  
Conceptually, these receptors have advantages over traditional TCRs in that they 
can be affinity enhanced to exhibit broader epitope reactivity or can be designed 
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to bind intact, non-processed viral proteins, similarly broadening the scope of 
HIV-specific CTL antigens.  Importantly, these receptors need to be designed to 
target sequences from which escape leads to a significant loss of viral fitness. 
 
Affinity enhanced TCRs for adoptive T cell therapy    
 
Joseph and co-workers demonstrated that polyclonal CD8 T cells could be 
redirected to target HIV-infected cells upon transduction with a lentivirus 
expressing the HIV Gag-specific SL9 TCR, which recognizes an HLA-A*02 
restricted Gag epitope SLYNTVATL (A2-SL9) and is associated with lower 
plasma virus levels during chronic HIV infection (21).  These cells lysed A2-SL9-
expressing target cells and were able to greatly reduce HIV infection in a SCID 
mouse model of HIV infection.   
 
The low inherent affinity of TCRs for their peptide-MHC binding partners, 
in the general range of 1-100µM, led researches to hypothesize that enhanced 
TCR binding affinity could lead to more powerful and sustained CTL responses 
(22).  Affinity enhancement was invoked successfully to modify the HLA-A*01 
restricted TCR specific for the NY-ESO-1 testes-specific tumor antigen.  In early 
clinical trials, 5/11 melanoma patients and 4/6 synovial cell sarcoma patients 
experienced complete or partial responses to NY-ESO-1 TCR-transduced T cell 
infusions (23).  Varela-Rohena et al. reported a similar method to enhance the 
A2-SL9 TCR, producing a TCR with picomolar affinity for its cognate antigen that 
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could control both CCR5- and CXCR4-utilizing strains of HIV better than the wild-
type (WT) A2-SL9 TCR (24).  Furthermore, the enhanced affinity TCR produced 
higher levels of the cytokines IL-2, MIP-1β, and IFNγ in response to A2-SL9-
expressing K562 artificial antigen presenting cells (aAPCs) and could control 
common SL9 escape variants not recognized by WT SL9 TCR.  A clinical trial 
(NCT00991224) was initiated to examine the effects of infusing WT or affinity 
enhanced SL9 TCR-transduced T cells in HIV-infected patients. 
 
Unfortunately, off-target toxicity that resulted in the death of two 
participants in a different trial with an affinity-enhanced HLA-A*01 restricted 
MAGE-A3-specific TCR for myeloma and melanoma patients caused concern 
over the ability of investigators to predict and model the target specificity of 
affinity enhanced TCRs (25).  In the MAGE-A3 trial, the high affinity TCRs gained 
the capacity to bind an epitope from the unrelated protein titin, expressed on 
contracting cardiac tissue, and resulted in cardiac toxicity(26).  As this protein is 
only expressed on beating cardiomyocytes and not traditionally cultured cardiac 
myocytes, this off-target killing capacity was not identified in preclinical toxicity 
tests.  The results of this trial underscored the need for thorough pre-clinical 
bioinformatics screening to identify all proteins containing the minimal amino acid 
sequences required for TCR recognition (26), combined with sophisticated cell 
culture techniques to identify off-target CTL reactivity to these proteins.  After 
careful discussions with the NIH, FDA, and IRB, NCT00991224 was closed 
before any patient received T cells transduced with a high affinity A2-SL9-specific 
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TCR.  The use of T cells expressing high affinity TCRs to target HIV, and 
particularly the HIV reservoir, is still an attractive concept, predicated upon a 
better understanding of the safety and specificity of these approaches. 
 
Chimeric antigen receptors for adoptive therapy 
 
Chimeric antigen receptors (CARs) are hybrid antigen receptors in which 
an extracellular antigen binding domain is linked to intracellular T cell activation 
domains, most commonly the CD3 zeta chain (27-29).  More recently, second- 
and third-generation CARs have been developed by including additional 
costimulatory domains such as 4-1BB and/or CD28 to increase proliferation and 
survival of modified cells (16, 30, 31).  Unlike a TCR, where antigen binding is 
physically uncoupled from signal transduction, CARs accomplish both of these 
functions from a single protein (Fig 1-2).  While this limits the repertoire of 
potential targets to surface expressed proteins, it allows T cells to bind targets in 
a high affinity, TCR-independent, MHC-unrestricted manner.  Unlike TCRs, 
CARs avoid the potential danger of mispairing with endogenous alpha and beta 
chains to generate off-target specificities and do not compete with TCRs for 
limited levels of endogenous CD3 complexes (27).  CARs have been employed 
successfully for cancer adoptive therapy, mediating remission in approximately 
80% of acute lymphocytic leukemia patients (32-34), and development for use in 
solid tumors is well under way (35, 36).     
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 CARs that bind the HIV Envelope (Env) glycoprotein, which is expressed 
on the surface of virions and HIV-infected cells, have been created using HIV-
specific antibody single-chain variable fragments or the host protein CD4 as the 
antigen binding moieties (37-39).  Pre-clinical experiments determined that CAR-
transduced CD8 T cells specifically lysed Env-expressing cells in vitro, and a 
gammaretroviral vector incorporating the CD4-based CAR entered four clinical 
trials (40-43).  Despite the possibility that surface expression of CD4 from the 
CD4 CAR could render transduced CD8 T cells susceptible to infection, the 
persistence of CAR T cells was striking, with the modified cells detectable in 98% 
of samples tested up to 11 years post infusion (43).  Linear mixed-effects 
modeling predicted a decay rate of over 16 years, with gene expression in 11/13 
patients.  This persistence was speculated to be the result of culture methods 
that resulted in a high proportion of central memory cells, combined with 
expression of a non-immunogenic transgene that may have been intermittently 
stimulated in vivo through low affinity interactions with MHC class II molecules or 
HIV Env due to bursts in virus replication (43).  The low affinity of CD4 for MHC 
class II likely prevented modified cells from attacking normal host cells (44).  
Although CAR-transduced cells could not be sorted in the post-infusion patient 
samples due to the inability to distinguish the CAR CD4 from endogenous CD4, 
patient PBMCs were stimulated with anti-CD4 loaded K562 aAPCs and zeta 
chain copy number was found to increase, suggesting the ability of CAR T cells 
to proliferate in response to antigen (43).  While none of the clinical trials led to 
durable reductions in viral loads, an important outcome of these trials was the 
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lack of related serious adverse events, indicating the safety of utilizing 
gammaretroviral vectors for T cell directed gene therapy approaches.  Moreover, 
the prolonged persistence of the transduced cells is promising, as earlier T cell 
infusion trials led to much more rapid decay rates.  Thus, we hypothesized that 
with the proper technological advances, CAR T cell expansion and functionality 
could be improved to facilitate sustained control over HIV replication.   
 
Dissertation research 
 
Considering that almost all of the major advances in ACT with CARs have 
been made for cancer-targeting CARs, it is interesting that the first CAR to reach 
the clinic was an HIV-targeting CAR.  Over the past 15 years, major technical 
advances in ACT have been realized, both in T cell growth and transduction 
procedures, and improved CAR design (14, 45).  We therefore sought to apply 
lessons learned from key oncology CAR studies to enhance HIV-targeting CARs 
in a systematic approach.      
 This thesis was designed to determine what components of CARs are 
critical for control over HIV replication in vitro and in vivo.  We maintained the 
hypothesis that a redesigned CAR which exhibited a greater cytotoxicity profile in 
vitro could be revisited as a critical component of an ACT-based HIV cure 
strategy.  We took a stepwise approach to optimize the CAR expression levels as 
well as the structural and functional features of the CD4 CAR.  We asked 
whether the CARs that functioned best in vitro similarly controlled HIV in 
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humanized mice.  This research will be discussed in Chapter 2.  During these 
experiments, it became apparent that the CD4 CAR rendered T cells expressing 
this construct susceptible to HIV infection, regardless of being a CD4 or a CD8 T 
cell.  Chapter 3 explored the outcome of protecting these T cells from HIV 
infection and is an ongoing area of research in the lab.  Finally, we asked 
whether we could model the latent reservoir to gain insight into the possibility of 
CARs facilitating a functional cure in HIV patients.  This research will be 
discussed in Chapter 4. 
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Figure 1-1. Overview of adoptive T cell therapy.  Adoptive T cell therapy (ACT) is the 
process of removing patients’ peripheral blood mononuclear cells (PBMCs), isolating the 
T cells, and modifying them for therapeutic purposes prior to returning to the patient.  
The T cells are typically activated and expanded to augment their functionality prior to 
reinfusion.  Additionally, antigen-specific cells (which respond to cancer or target 
peptides) can be selected for.  More recently, T cells have been modified to express T 
cell receptors (TCRs) or chimeric antigen receptors (CARs) to redirect polyclonal T cells 
to target a specific antigen.  Schematic taken from Sharpe, M. and Mount, N. 2008.  
Disease Models & Mechanisms.   
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Figure 1-2. Comparison of T cell receptor (TCR) and chimeric antigen receptor 
(CAR) structure.  A TCR is comprised of the αβ heterodimer, which is responsible for 
binding to the complex of antigenic peptide presented by major histocompatibility 
complex (MHC) molecules, in complex with various CD3 signaling chains which transmit 
intracellular activation signals.  Various costimulatory molecules including CD28 and 4-
1BB or OX40 can localize near the TCR and participate in cellular activation.  In 
contrast, a CAR fuses the extracellular antigen binding domain, typically a single chain 
variable fragment adapted from an antibody, directly to the CD3 zeta T cell activation 
domain.  Additional intracellular costimulatory domains, taken from CD28, 4-1BB, OX40, 
among others, can be included within the intracellular portion of the CAR.  Binding  
Schematic adapted from Gao, J. et al.  2008.  Trends in Immunology.   
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CHAPTER 2 – Supraphysiologic control over HIV replication mediated by 
CD8 T cells expressing a re-engineered CD4-based chimeric antigen 
receptor 
 
 
Abstract 
 
HIV is adept at avoiding naturally generated T cell responses; therefore, 
there is a need to develop HIV-specific T cells with greater potency for HIV cure 
strategies.  Starting with a CD4-based chimeric antigen receptor (CAR) that was 
previously used safely in humans, we optimized the vector backbone, promoter, 
HIV targeting moiety, and transmembrane and signaling domains to determine 
which components augmented the ability of T cells to control HIV replication.  
This re-engineered CAR was at least 50-fold more potent in vitro at controlling 
HIV replication than the original CD4 CAR, or a TCR-based approach, and 
substantially better than broadly neutralizing antibody-based CARs.  A 
humanized mouse model of HIV infection demonstrated that T cells expressing 
optimized CARs were superior at promoting CAR T cell expansion, protecting 
CD4 T cells, and reducing viral loads compared to the original, clinical trial CAR.  
Moreover, in a humanized mouse model of HIV treatment, CD4 CAR T cells 
containing the 4-1BB costimulatory domain controlled HIV spread after ART 
removal better than analogous CAR T cells containing the CD28 costimulatory 
domain.  Together, these data indicate that potent HIV-specific T cells can be 
generated using improved CAR design and that CAR T cells could be important 
components of a HIV cure strategy.  
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Introduction 
 
 
It is well established that T cells play an important role in controlling HIV-1 
(HIV) replication, and that HIV-infected individuals develop robust HIV-specific T 
cell responses (6, 18).   However, HIV evades the endogenous T cell-mediated 
immune response by altering key residues required for T cell recognition and 
downregulating class I major histocompatibility complexes (MHC) (1, 2).  
Additionally, HIV-mediated depletion of HIV-specific CD4 T helper cells and the 
chronic persistence of the virus functionally impair HIV-specific CD8 T cells so 
that, in most individuals, T cells are unable to control HIV replication (3).  
Although antiretroviral therapy (ART) can suppress HIV replication by many 
orders of magnitude, it fails to eliminate the virus, forcing HIV-infected individuals 
to be treated by ART regimens for the rest of their lives.  ART also reduces the 
number of HIV-specific T cells present, due to a massive reduction in HIV 
antigen, and the T cells that remain often have functional defects (46, 47).  Thus, 
at the time of ART removal when the number of HIV producing cells is minimal, 
the resident HIV-specific T cell immune response is ill-equipped to control the re-
emerging infection and uniformly fails, with viral loads returning to patient-specific 
set point within weeks after ART removal (48).  As a result, we and others have 
postulated that instead of relying on the endogenous immune response to control 
HIV replication as part of an HIV cure strategy, the introduction of a potent 
engineered immune response designed to overcome HIV’s escape mechanisms 
will be required to provide durable control HIV in the absence of ART (49-51). 
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Previous ACT trials have demonstrated that simply reinfusing expanded 
patient T cells does not result in durable control over HIV replication (49).  Thus, 
both the quality and quantity of infused HIV-specific T cells must be enhanced for 
a sustained therapeutic benefit.  Attempts to manufacture better T cells for ACT 
have recently been made through antiviral transgenes, coreceptor editing, and 
redirecting T cells with HIV-specific T cell receptors (TCRs) or chimeric antigen 
receptors (CARs) (4, 49).  CARs consist of an extracellular antigen binding 
domain fused to intracellular T cell activation domains (52).  These synthetic 
receptors can redirect T cells to recognize viral proteins independent of antigen 
processing, TCR, and MHC.  CARs targeting CD19 have revolutionized the 
treatment of leukemia and lymphomas through their ability to persist and 
maintain durable anti-tumor effects in vivo (53, 54).   Of note, the first CAR to 
enter human trials redirected T cells to target the GP120 region of the HIV 
Envelope (Env) glycoprotein (40-42).  This was achieved by fusing the 
extracellular and transmembrane domains of CD4, the cellular receptor for HIV, 
to the CD3-zeta cytoplasmic region (CD4-zeta).  HIV-specific cytotoxicity was 
established in vitro, and safety was demonstrated in vivo, with transient 
reductions in HIV RNA, DNA, and quantitative HIV outgrowth assays (37, 39, 41, 
42, 55).  A long-term follow up study determined the half-life of the CAR-modified 
cells to be over 16 years, with CAR expression up to 10 years post infusion and 
no serious adverse events (43).  However, the CD4-zeta CAR did not lead to 
sustained reductions in viral loads or the viral reservoir, and the clinical data were 
not sufficiently promising to warrant additional development. 
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Subsequent to the HIV CAR clinical trials, a number of advances have 
been made in CAR design for optimal antitumor responses.  Xenograft models 
and clinical trials have established that costimulation augments function,  
proliferation, and survival in vivo (16, 56, 57).  In addition, CAR structural and 
signaling domains have been found to greatly impact T cell function and 
susceptibility to exhaustion (58, 59).  For example, it was recently demonstrated 
that CAR costimulatory domains influence T cell metabolic and phenotypic 
profiles, with 4-1BB promoting a central memory phenotype and CD28 promoting 
an effector memory phenotype (60).  While there has recently been a renewed 
interest in utilizing CARs to control HIV, including efforts to increase CAR T cell 
function and survival, a systematic optimization of CAR T cell cytotoxicity was 
lacking (61, 62).  We sought to apply the lessons learned from engineering CARs 
for hematologic malignancies to optimize the CD4 CAR for superior control over 
HIV replication.  We demonstrate here that changing the CAR expression vector, 
promoter, transmembrane, and costimulatory domains improved control over HIV 
in vitro by over 50-fold.  In vivo, humanized mice engrafted with T cells 
expressing these optimized vectors had significantly higher CD4 T cell counts, 
greater CAR+ CD8 T cell proliferation after HIV infection, and 90% less HIV RNA, 
compared to mice that received T cells transduced with the clinical trial CD4-zeta 
CAR.  An HIV treatment model demonstrated superior control over HIV 
replication by 4-1BB containing CARs, compared to equivalent CARs containing 
the CD28 costimulatory domain.  These data provide a compelling reason to 
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revisit human clinical trials with CD4 CARs that have been optimized for control 
over HIV in vivo for use in HIV cure studies. 
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Results 
 
 
Lentiviral backbone augments CAR expression and control over HIV 
replication.  Preclinical studies testing the original CD4-zeta CAR showed that T 
cells expressing this construct had equivalent antiviral activity to naturally 
generated HIV-specific T cells (55).  We hypothesized that the reason these 
clinical trials failed to demonstrate durable clinical responses was that the T cells 
used in these trials were no more potent than the endogenous HIV-specific T cell 
response.  Therefore, we sought to optimize the CD4-zeta CAR based on 
lessons learned from cancer-specific CARs to augment control over HIV 
replication (14).  To do this, we optimized each component of the CAR in a step-
by-step manner.  We first addressed to what extent the vector backbone 
contributes to the ability of CAR+ CD8 T cells to control HIV.  The original CD4-
zeta CAR was expressed by a murine retroviral vector (MMLV-based).  Since 
MMLV-based vectors target promoter regions and  lentiviral vectors (HIV-based) 
integrate preferentially into open reading frames, we reasoned that lentiviral 
vectors would result in higher expression than MMLV-based vectors (63).  We 
generated the MMLV clinical trial construct and an analogous lentiviral vector, 
both with the PGK promoter, and transduced primary human CD8 T cells.  
Lentiviral transduction consistently resulted in a ~10-fold higher median 
fluorescence intensity (MFI) of CAR expression compared to MMLV retrovirus 
(Fig 2-1 A-D).  To determine whether the higher transgene expression was the 
result of more vector integrations per cell, we measured the integrated vector 
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copy number in the different T cell populations using a previously established 
assay (43).  We found that the MMLV-based vector had almost twice the number 
of integrations compared to the HIV-based vector (Fig 2-1 E), indicating that the 
higher transgene expression of the HIV-based vector is due to its intrinsic 
properties.  
A co-culture assay was used to compare the different CARs in terms of 
their ability to control HIV replication (Fig 2-1 F).  In this assay, HIV-infected CD4 
T cells were cultured with either nontransduced (NTD) CD8 T cells or CAR 
transduced CD8 T cells, and the ability of the effector CD8 T cells to control HIV 
spread was measured over 7-14 days.  To distinguish between HIV spread 
throughout the CD4 T cells and infection of the CD4 CAR+ CD8 T cells, we gated 
separately on the CD8 negative and the CD8 positive T cells, and then analyzed 
intracellular p24 (Gag) in CD4 T cells and CD8 T cells, respectively (see gating 
strategy in Fig 2-2).  High levels of HIV replication were observed in CD4 T cells 
co-cultured with NTD CD8s (Fig 2-1 G).  In contrast, CD8 T cells transduced with 
either a MMLV-based or HIV-based CAR vector were able to control HIV 
replication at a 1:1 E:T ratio, similar to what was observed in previous studies of 
this strategy (37, 39, 55).  However, upon diluting the CAR transduced CD8 T 
cells to lower E:T ratios, T cells transduced with the HIV-based vector were 
superior at controlling HIV replication over time (Fig. 2-1 G-J).  Ultimately, neither 
population of transduced CD4 CAR CD8 T cells could control HIV spread at a 
1:50 E:T ratio.  
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In contrast to recent reports that CD4 CAR transduced CD8 T cells are 
susceptible to infection by cell-free virus (61, 62), we were only able detect 
intracellular Gag in CAR+ CD8 T cells after diluting to low E:T ratios with HIV-
infected CD4 T cells (Fig 2-1 H, Fig 2-3).  Of note, there was a small proportion 
of nontransduced CD8 T cells that stained positively for Gag, regardless of the 
E:T ratio.  This was likely the result of the ability of CD8 T cells to transiently 
express CD4 after activation (64-67).  This data highlights the complex 
relationship between CD4 CAR expression and susceptibility to HIV infection.  At 
high E:T ratios the CAR+ CD8 T cells are able to fully suppress HIV replication, 
and thus they and the co-cultured CD4 T cells are protected from HIV infection.   
However, at low E:T ratios, the CAR+ CD8 T cells are no longer able to suppress 
HIV replication, and the virus is able to spread throughout both populations of 
cells (Fig 2-1 H).   
 
EF1α promoter and CD8α transmembrane domains improve CAR 
expression and control over HIV.  Transgene expression in T cells wanes 
when driven by the PGK promoter as T cells rest down.  In contrast, the EF1α 
promoter induces higher expression that is better sustained as T cells return to 
quiescence (16).  We hypothesized that the EF1α promoter might be beneficial in 
our system, since greater CAR MFI expression correlated with better control over 
HIV (Fig 2-1).  Under the EF1α promoter, CAR expression MFI increased ~10-
fold compared to the PGK promoter (Fig 2-4 A and B).  Next, we substituted the 
CD8α transmembrane (TM) domain in place of the CD4 TM domain to promote 
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CAR dimerization, remove CD4 TM motifs targeted by HIV Vpu for 
downregulation, decrease homology to the HIV cellular receptor, and ultimately 
augment cytotoxicity (68-71).  Greater control over HIV replication was achieved 
by both modifications individually, and a combination of the two modifications led 
to complete control over HIV replication down to a 1:50 E:T ratio (Fig 2-4 C and 
E).  Substitution of the CD8α TM domain decreased infection of CAR CD8 T cells 
regardless of the promoter used at the 1:25 and 1:50 E:T ratios (Fig 2-4 D).  We 
observed similar results when examining the culture supernatants for p24 Gag 
(Fig 2-5).  However, as seen in Fig 2-1 and Fig 2-3, the CAR+ CD8 T cells could 
be diluted to the point where they no longer controlled HIV infection and 
succumbed to infection themselves (Fig 2-4D).  To ensure this was not an 
artifact of gating on a few CD8 T cells, we performed a larger scale experiment 
where at least 1x104 CD8 T cells were collected per condition and the infection 
pattern was the same (Fig 2-6).  Thus, altering the viral vector, promoter, and 
transmembrane domains afforded a 50-fold increase in potency over the clinical 
trial MMLV-based retrovirus, resulting in complete control over HIV replication at 
a 1:50 E:T ratio in vitro (Fig 2-4 E and F).   
 
Re-directed T cells expressing a CD4 CAR are 100-fold more potent than re-
directed T cells specific for B57-KF11.  Elite controllers are rare individuals 
who control HIV replication in the absence of ART.  Certain HLA alleles, such as 
HLA-B57, are overrepresented in these cohorts, suggesting that T cell responses 
play a key role in controlling their virus (72).  Therefore, we wished to determine 
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whether T cells expressing a re-engineered CD4 CAR (with the EF1α promoter 
and CD8α TM) could control HIV replication better than T cells expressing a 
HLA-B57 restricted TCR that is associated with better control over HIV 
replication.  To do this, we generated an analogous lentiviral vector that 
expressed the TCRα and TCRβ chain under the EF1α promoter to confer 
specificity for B57-KF11 epitope (HIV p24 Gag epitope KAFSPEVIPMF) (Fig 2-7 
A).  To confirm these cells recognized Gag-expressing cells, we incubated them 
with target CD4 T cells from HLA-B57+ individuals that were transfected with Gag 
RNA, or Pol RNA as a negative control, and detected a robust Gag-specific 
cytokine response (Fig 2-7 B).  Next, we compared the ability of KF11 TCR 
versus CD4 CAR transduced CD8 T cells to limit HIV spread in HLA-B57 CD4 T 
cells.  While KF11 TCR-transduced CD8 T cells reduced HIV replication down to 
a 1:25 E:T ratio, complete control over HIV replication was never achieved (Fig 
2-8).  In contrast, the re-engineered CD4 CAR controlled HIV almost completely 
down to a 1:100 E:T ratio.  These data suggest that the synthetic CD4 CAR 
approach is more potent than the natural TCR based approach and that the CD4 
CAR approach will likely be more effective as a cellular therapy tool compared to 
T cells transduced with a patient-derived, natural TCR.   
 
CD4-based CARs control HIV more effectively than broadly neutralizing 
antibody-based CARs.  The most commonly used CAR ectodomains are 
antibody-derived single chain variable fragments (scFvs) (52).  Over the past 
several years, a number of HIV-specific antibodies have been described that bind 
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or neutralize HIV with high affinity and/or target a wide breadth of viruses (73).  
We tested whether the use of scFvs to redirect T cells to HIV was superior to the 
use of CD4.  In addition, we wanted to test whether CD8 T cells expressing scFv-
based CARs were less susceptible to HIV infection than CD4-based CARs.  A 
panel of scFvs derived from the VRC01, 3BNC60, PG9, PGT128, or PGDM1400 
parental antibodies were generated due to their neutralization breadth and/or 
potency against HIV and cloned into the most effective CAR design identified in 
Fig 2-4, with the EF1α promoter and the CD8α TM domain (74, 75).  To 
determine that each scFv CAR had folded properly, could interact with Env, and 
promote CD8 T cell lysis, we measured specific lysis of chromium labeled K562 
target cells expressing the Env protein from the HIV YU2 strain.  All CARs were 
capable of lysing Env-expressing targets to a similar degree, indicating that these 
CARs recognized HIV Env (Fig 2-9 A).  Many of the scFv CARs consistently 
produced higher levels of intracellular cytokines in response to Env-expressing 
targets when compared to the CD4 CAR (Fig 2-10 A).  However, when co-
cultured with HIV-infected CD4 T cells, the CD4 CAR controlled HIV better than 
all of the scFv-based CARs (Fig 2-9 B and D, and Fig 2-10 B).  Interestingly, the 
PGT128 CAR repeatedly controlled HIV better than the other scFvs tested, 
despite being less broad and less potent in neutralization studies than 
PGDM1400 (75).  Surprisingly, at low E:T ratios we detected high levels of 
intracellular Gag in the scFv CD8 T cells, similar to CD4 CAR+ T cells diluted to a 
1:200 E:T (Fig 2-9 C).  This was not a byproduct of lentiviral transduction or 
generic CAR expression, as this was not seen for GFP-transduced or CD19 
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CAR-transduced cells (Fig 2-10 C) and thus appears to depend on HIV binding 
ability, possibly concentrating the virus near the CAR-transduced cell membrane.  
Based on the in vitro superiority of the CD4 CAR against this limited scFv subset, 
and the inherent difficulty of HIV escaping from CD4 binding, we chose to pursue 
development of CD4-based CARs for in vivo testing.  
 
ICOS, CD27, and 4-1BB costimulation impair control of HIV replication in 
vitro.  T cells require costimulatory signals for proliferation, effector function, and 
long-term survival (76).  Costimulatory domains, such as CD28 and 4-1BB, have 
been incorporated into recent CAR designs for durable CAR T cell responses in 
vivo (56).  In chronic HIV infection, T cell dysfunction and exhaustion have been 
well documented, and decreased CD28 and 4-1BB signaling impair cytolytic and 
effector function (47, 77, 78).  Therefore, we generated a panel of CD4 CARs 
that incorporated a variety of costimulatory domains in conjunction with the CD3-
zeta domain, including CD28, 4-1BB, CD28+4-1BB, OX40, ICOS, or CD27 and 
tested their ability to control HIV infection in vitro.  CD8 T cells expressing CARs 
that contained 4-1BB, CD27, or ICOS costimulation domains did not control HIV 
as effectively as T cells expressing CARs that expressed the other costimulatory 
domains, suggesting that these costimulatory pathways interfered with control of 
HIV replication (Fig 2-11).  Regardless of the costimulatory domain, the control 
seen with these CD4 CARs was superior to the control seen with an HIV-specific 
TCR (Fig 2-8) or with scFv based CARs (Fig 2-9).  While CD28 promoted better 
control over HIV in vitro compared to 4-1BB, discrepanices between the in vitro 
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and in vivo activity of cancer-specific CARs containing 4-1BB had been reported 
(58, 60).  Thus, we were curious if this held true for HIV-specific CARs, and 
decided to further characterize the safety profile and in vivo efficacy of CD4 
CARs expressing either CD28 or 4-1BB.   
 
CD4 CARs respond to Env+ cells and not MHC class II+ cells.  Preclinical data 
demonstrated that T cells expressing the clinical trial CD4-zeta CAR did not kill 
Raji cells, which express high levels of MHC class II, the low affinity ligand of 
CD4 (39).  However, we were concerned that our optimized, highly expressed 
CD4 CAR might recognize MHC class II expressing cells.  To test this, we 
measured CAR+ CD8 T cell responses against K562 cells stably expressing high 
levels of the HLA-DR*0401 allele (Fig 2-12).  CD8 T cells were transduced with 
optimized CD4 CARs containing CD3-zeta alone or with the 4-1BB and CD28 
costimulatory domains and cultured with unmodified K562 target cells, HLA-
DR*0401+ K562 cells, or HIV YU2 Env+ K562 cells.  CAR transduced CD8 T cells 
produced IL-2, CD107a, IFN-γ, and MIP-1β in response to HIV Env+ targets but 
not in response to HLA-DR+ or parental K562s, with the most robust production 
by CD28-containing CAR T cells (Fig 2-13 A).  A small MIP-1β signal was 
observed for all CARs mixed with parental or HLA-DR expressing targets that 
was not observed with NTD controls, likely due to some constitutive signaling 
observed in CAR T cells (79).  It has been shown that autocrine production of 
beta chemokines by CMV-specific T cells decreases CCR5 expression and 
protects these cells from HIV infection, so this low-level MIP-1β production may 
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help protect the CAR+ CD8 T cells in vivo (80).  Importantly, no difference in 
cytokine or CD107a production was detected by CAR T cells cultured with 
parental versus MHC class II expressing cells, suggesting that our optimized 
CD4 CARs do not facilitate off-target recognition of MHC class II.  Coculturing the 
optimized CD28-containing CAR with HLA-DR+ K562 cells over an extended 
period further confirmed the lack of off-target responses.  We mixed HLA-DR+ 
K562 cells 1:1 with HLA-A2+ K562 control cells and did not see a change in the 
ratio of the two K562 populations over time (Fig 2-13 B and C), suggesting that 
the re-engineered CAR will exhibit a similar safety profile in humans as the 
original CD4 CAR. 
 
Optimized CAR T cells control HIV replication better and expand to greater 
levels in vivo than first generation CAR T cells.  CD19-specific CARs 
containing the CD28 signaling domain had superior in vitro activity than those 
containing the 4-1BB signaling domain, but the 4-1BB containing CARs proved 
superior in humanized mouse models and in patients (16, 54, 81).  We wished to 
determine whether the same was true for HIV-targeting CARs.  In addition, we 
wanted to determine if our optimized CD4 CARs could control HIV better in vivo 
then the original CD4-zeta CAR that was tested in the clinic.  To do this, we 
utilized a NSG humanized T cell (NSG hu-T cell) mouse model.  In this model, 
detectable T cell engraftment (>10 cells per µl of blood) takes 2-3 weeks, and 
over the next 2-3 months T cell engraftment slowly rises until the mice become 
sick due to xenograft-mediated GVHD (82, 83).  HIV infection prevents CD4 T 
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cell expansion and, paradoxically, makes the animals healthier.  Thus, evidence 
of GVHD and high levels of CD4 T cell engraftment are strong evidence that anti-
viral agents, such as CAR T cells in this case, are effective.  Four groups of mice 
were compared with different CD8 effector cell populations: nontransduced 
(NTD), transduced with the optimized lentiviral vector containing either 4-1BB 
(BBz) or CD28 (28z) costimulatory domains, or transduced with the clinical trial 
MMLV-based vector (MMLV-CD4z).  Pre-infection, baseline CD4 T cell counts 
did not differ significantly between the NTD, BBz, or 28z groups, and were 
significantly higher for the MMLV-CD4z treated mice (Fig 2-14 A).  After HIV 
infection, we observed that mice infused with T cells expressing the BBz or 28z 
construct had a 17-fold and 177-fold expansion of the number of human CD4 T 
cells, respectively (Fig 2-14 B).  In contrast, endpoint CD4 counts were depleted 
in NTD or MMLV-CD4z mice (Fig 2-14 B).  Examination of the number of CAR+ 
CD8 T cells in the different mouse cohorts revealed 389-fold, 587-fold, and 2-fold 
expansions in the BBz, 28z, and MMLV-CD4z T cells, respectively (Fig 2-14 C 
and D), suggesting there is a correlation between the ability of CAR T cells to 
expand and the ability to protect CD4 T cells from HIV-mediated destruction.   
We also examined viral loads.  Since HIV replication is highly dependent 
on the number of CD4 T cells present in this model, we normalize viral load to 
the number of CD4 T cells present at a given timepoint to fairly compare different 
treatment groups.  Seven days following HIV infection, BBz CAR T cells exhibited 
the greatest control over virus replication, with many mice showing undetectable 
virus loads, whereas plasma from NTD, 28z, and MMLV-CD4z treated animals 
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contained approximately 1 normalized copy of HIV RNA per µl (Fig 2-14 E).  
Eighteen days post infection, the median copy number of HIV RNA was reduced 
by more than 10-fold in both BBz and 28z treatment groups, compared to the 
mice that were treated with NTD T cells (Fig 2-14 F).  However, MMLV-CD4z 
treated mice has similar HIV RNA loads as NTD treated mice.  Thus, the 
optimized CARs are superior at protecting CD4 T cells, promoting CD8 T cell 
expansion, and controlling HIV replication in vivo, with BBz CARs superior in 
preventing the early spread of HIV.   
 
CAR T cells containing 4-1BB outperform CAR T cells containing CD28 in 
an HIV-treatment model.  After establishing that optimized CARs can function in 
humanized mice to control HIV replication, we next wanted to model CAR 
treatment of pre-established HIV infections and further examine whether 4-1BB 
or CD28 costimulation promoted better in vivo control.  To mimic how CARs 
would be applied in a clinical trial, we injected CAR T cells into NSG mice with a 
previously established pool of HIV-infected T cells in the presence of ART and 
monitored virus rebound after ART was stopped (Supplementary Fig 2-15).  
 After three days of HIV infection in the presence of ART, the peripheral 
blood CD4 T cell counts were similar for all groups (Fig 2-16 A).  However, at 18 
days post ART removal CD4 T cell depletion was apparent in NTD and 28z CAR 
treated mice, with significantly higher CD4 T cell counts in the BBz treatment 
group (Fig 2-16 B).  By the endpoint bleed, the 28z CARs demonstrated 
increased protection of CD4 T cells, and only the NTD mice had significantly 
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lower CD4 T cell counts (Fig 2-16 C).  In contrast, mock infected mice 
maintained similar CD4 T cell counts in all treatment groups at all timepoints 
(Supplementary Fig 2-16 A-C).  Interestingly, endpoint CD4 T cell counts were 
similar in this experiment for both BBz and 28z CAR treatment groups (Fig 2-16  
B and C), as opposed to Fig 2-14 where CD4 counts were significantly higher in 
28z treated mice.  Ten days post ART removal, the CAR treated mice had higher 
peripheral blood CD8 T cell counts compared to NTD mice (Fig 2-16 D).  This 
effect was HIV-specific, as all mock treated mice had similar CD8 T cell counts 
(Fig 2-17 D).  However, by 18 days post ART removal the CD8 T cell counts 
were significantly higher in mice that received BBz CARs compared to NTD or 
28z CAR-treated mice (Fig 2-16 E and F).  This BBz CAR proliferation effect was 
partially antigen independent, as greater BBz CAR expansion was also seen in 
mock treated mice (Fig 2-17 E and F), consistent with the notion that 4-1BB 
signaling in tumor-specific CARs promotes T cell survival (16, 58, 84) 
Prior to CD8 T cell injection, while the animals were on ART, most mice 
had undetectable viremia and 3/20 had very low levels of plasma HIV RNA (<1 
copy per ul, Table 2-1).  Ten days post ART removal, all NTD mice had 
detectable plasma RNA, whereas all CAR treated mice had very low or 
undetectable HIV, as measured by plasma HIV RNA (Fig 2-16 G).  Similar 
patterns of control were detected via measuring plasma HIV p24 Gag protein 
using an ultrasentive assay (Fig 2-18).  However, after 18 days post ART 
removal, 28z treated mice experienced an increase in HIV replication and had 
similar plasma levels of HIV as NTD mice, whereas the BBz mice maintained 
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significantly better control (Fig 2-16 H, I and Fig 2-18 B).  Together, these data 
suggest that a CD4 CAR containing the 4-1BB zeta signaling domain will be most 
effective in HIV cure strategies because 1) its ability to act rapidly to prevent HIV 
spread (Fig 2-14 E and F), 2) its ability to durably prevent viral rebound (Fig 2-16 
H and I), and 3) its ability to promote T cell survival in the absence of antigen 
(Fig 2-17 E and F). 
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Discussion 
 
 
T cell control over virus replication is enabled through potent effector 
mechanisms that ensure rapid killing and prevent dissemination of progeny 
viruses (85).  However, HIV employs multiple strategies to evade T cell 
recognition and control.  For instance, the HIV Nef protein modulates expression 
of MHC class I, CD28, and other proteins involved in immune recognition to 
evade cytotoxic T lymphocytes (CTL) (2, 86).  Additionally, the phenomenal 
capacity of HIV to modify its MHC class I restricted peptide antigens promotes 
escape from CTL responses (1).  Moreover, due to chronic HIV persistence, 
CTLs become exhausted and progressively lose their effector functions (47).  For 
these reasons, there is a strong rationale to develop HIV-specific T cells with 
enhanced, supraphysiologic ability to control HIV replication for therapeutic 
studies aimed to establish long-term control, or a “functional cure,” in the 
absence of antiretroviral treatment.   
We hypothesized that we could re-engineer the original CD4 CAR that 
was tested in the clinic and determined to be safe and long lived, but lacked 
potent antiviral activity, to develop T cells that were far more effective in 
controlling HIV infection (40-42).  We found that switching from a MMLV-based 
gammaretroviral vector to an HIV-based lentiviral vector resulted in much higher 
CAR surface expression, and expression was further augmented upon 
substituting the EF1α promoter for than the PGK promoter, consistent with 
previous cancer-targeting CAR studies (16).  Higher CD4 CAR expression in 
primary human CD8 T cells correlated with improved control over HIV replication.  
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However, this was not a perfect correlation, as incorporating the CD8α TM 
domain rather than CD4 TM domain resulted in lower CAR expression but 
improved control over HIV replication.  We favor two non-mutually exclusive 
explanations of this finding:  the CD8α TM domain facilitates less HIV fusion than 
the CD4 TM domain, making cells less susceptible to CD4 CAR-mediated 
infection; and the CD8α TM domain promotes dimerization, which may potentiate 
signaling (16, 68, 70).  Indeed, improved control over HIV replication by CD4 
CARs inversely correlated with the susceptibility of CAR+ CD8 T cells to become 
infected, suggesting that HIV infection limits CAR effector activity. 
We found that, despite similar levels of specific lysis and stronger cytokine 
production in response to Env+ K562 cells, scFv-based CARs could not control 
HIV replication as well as CD4-based CARs in vitro, suggesting that CD4 may 
recognize HIV Env expressed on the cell surface faster than the scFvs we 
examined.  Although it is certainly possible that additional scFv CARs could have 
superior activity than those described here, we favor the use of T cells 
expressing the CD4 CAR due to its extensive clinical safety profile, lack of 
immunogenicity, and the dependence HIV shows for using CD4 as an entry 
factor (43).  While escape from antibody targeting is common in HIV, the reliance 
on CD4-mediated entry suggests that escape from CD4 binding will impose 
significant, if not lethal, fitness costs. As safety and efficacy of this re-engineered 
CAR are demonstrated in HIV-infected individuals, combinatorial approaches 
with scFv based CARs may further augment control of HIV replication in the 
absence of ART. 
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The improved control exhibited by the re-engineered CD4 CAR is 
impressive, with at least a 50-fold augmentation in control over HIV replication 
(Fig 2-19).  Many studies have used similar methods to study the ability of 
previous CD4 CAR designs and HIV-specific T cells to limit HIV replication in 
vitro and an E:T ratio of 1:1 was generally required to obtain complete control, in 
line with what we observed with these constructs (37, 39, 55).  The superiority of 
CARs compared to a TCR-based approach may be due to antigen-binding 
affinity, target cell-binding avidity, T cell activation kinetics, or bypassing the 
detrimental effects HIV Nef (2).  Overall, the potent control achieved by the re-
engineered CARs provides optimism for clinical utility and achieving a functional 
cure.   
We opted to use a NSG hu-T cell mouse model in which human T cells 
isolated from human donors would be manufactured in an analogous manner as 
a clinical trial.  While there are certainly drawbacks to this model, such as GVHD 
and the inability to replace CD4 T cells once they are depleted by HIV infection, 
this model has been successfully used in preclinical, FDA mandated biotoxicity 
and efficacy studies (83, 87) and has mirrored the outcome of several clinical 
trials exploring gene therapy approaches to treat HIV infection (82, 83).  Our in 
vivo results demonstrated that the re-engineered CD4 CARs had potent antiviral 
activity, vastly superior to the original CD4-zeta CAR construct.  Interestingly, we 
saw superior control by the 4-1BB containing CARs both early in infection within 
the HIV prevention model and more durable control at late timepoints within the 
treatment model, compared to mice treated with CD28 containing CARs.  In 
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contrast to the mouse data, our in vitro studies show that CD28 costimulation 
promoted higher cytokine production and better control over HIV replication, 
relative to a CD4 CAR containing 4-1BB costimulation.   
One way to reconcile the difference between our in vitro and in vivo finding 
is to consider CAR T cell expansion kinetics.  We showed in vitro that if the CAR+ 
CD8 T cells are in sufficient numbers, they can prevent the spread of infection in 
all cells; however, if they fall below a critical level, then both the CD4 T cells as 
well as the CAR+ CD8 T cells are infected and HIV begins to spread.  In our HIV 
treatment model, effective early control results in an expansion of more CD4 T 
cell targets.  If the CAR+ CD8 T cells fail to expand in proportion to the CD4 T 
cells or are depleted by HIV, then they may fall below the critical threshold 
required to control HIV replication.  Differences in the relative expansions of BBz 
and 28z CARs in vivo, which may partially be due to better antigen-independent 
expansion of BBz, may underlie the differences in HIV control observed between 
Fig 2-11 and Fig 2-16.  In support of this hypothesis, we observed less 28z CD8 
T cell expansion relative to BBz and this correlated to less viral control (Fig 2-
16).  Moreover, by the end of the HIV-prevention model, shown in Fig 2-14, 
similar control by either CAR resulted when the 28z CARs expanded to a similar 
degree as the BBz CARs.   
In any case, one would predict using CCR5 ZFNs (88), C34 based fusion 
inhibitors (87), or other methods to protect CD4 CAR expressing cells from HIV 
infection would further potentiate the therapeutic potential of CD4 CAR T cells.  
In addition, the ability to persist in the absence of antigen may be important for a 
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functional cure in which durable T cell control may need to last for decades.  
Together, our data suggests that CD4 CARs containing the 4-1BB costimulation 
domain may be the most effective way to deliver T cell control of HIV replication.  
Unfortunately, there is no animal model that faithfully mirrors HIV infection in 
humans, and issues of trafficking, immune privilege, and durability are difficult to 
fully model in humanized mice.  Nonetheless, these data provide the rationale to 
re-visit the clinical utility of CD4 CAR in HIV-infected individuals and provide 
optimism for CAR T cells to achieving durable control over HIV in the in the 
absence of ART. 
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Materials and methods 
 
Plasmid construction. pRT43.2 GFP, the backbone of the original clinical trial 
vector, was obtained courtesy of Dr. Maribeth Eiden (37, 89)  A restriction site 
linker was inserted into the PstI and SalI sites, removing the CMV promoter.  The 
PGK promoter CD4-zeta sequence was amplified from pRRL.PGK.F3 (a gift of 
Dr. Tom Dull) with oligos 5’ GTATCGATCACGAGACTAGC and 
5’TTAAACCGGTGTCTGGCCTTTGAGTGGTGA and inserted into XhoI and AgeI 
sites in the linker within pRT43.2.  pTRPE CD4 zeta was created by amplifying 
the CD4 extracellular domain was amplified from pRRL.PGK.F3 with primers: 5' 
TTAATGGGATCCATGAACCGGGGAGTCCCTTT and  5' 
AAGGACTTCCGGATGGCTGCACCGGGGTGGACCATG-3' and inserted into 
the BamHI and BspE1 sites in the pTRPE backbone containing the CD8α 
extracellular hinge and transmembrane domains and the 4-1BB and CD3 zeta 
intracellular costimulatory domains (90).  pTRPE lentiviral vectors containing the 
CD8α hinge-CD8αTM-CD3ζ  or the CD8α hinge-CD28TM-CD28-CD3ζ 
intracellular costimulatory domain (ICD) were used as template to PCR amplify 
the hinge-TM-and ICD region into the BspE1 and Sal1 sites with primers:5’ 
GGGACACTCCGGAACCACGACGCCAGCGCCGCG and 5’ 
GGGACACGTCGACTTAGCGAGGGGGCA.  A lentiviral vector that expressed a 
B57 restricted TCR capable of recognizing HIV p24Gag epitope KAFSPEVIPMF 
(pTRPE B57-KF11) was generated by synthesizing the TCRα and TCRβ gene 
sequence (IDT, the TCR sequences were a generous gift of Xu Yu and Bruce 
Walker (91)).  The TCRα and TCRβ gene sequence was separated by the T2A 
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for expression of both TCR genes as previously described (24).  VRC01, 
3BNC60, PGT128, and PGDM1400 scFv CARs were generated from the 
published parental antibody sequences, with a light-linker-heavy chain 
configuration (75, 92-95).  The linker sequence is: GGSSRSSSSGGGGSGGGG.  
Amino acid sequences were codon-optimized (Geneart) and synthesized as 
double-stranded DNA fragments (IDT or Geneart), flanked with suitable 
restriction sites and cloned into pTRPE plasmids with the BamHI and BspE1 
sites.  The PG9 scFv was obtained as a generous gift from Dr. Phil Johnson and 
cloned into the pTRPE plasmid with the BamHI and BspE1 sites.  The amino acid 
sequences are found in Fig 2-20. 
 
Virus production and transduction. To generate lentiviral particles, expression 
vectors encoding VSV glycoprotein, HIV Gag and Pol, and Rev (pTRP pVSV-G, 
pTRP g/p.RRE  pTRP.REV) were synthesized by DNA 2.0 and transfected onto 
HEK293T cells with pTRPE transfer vectors using the Lipofectamine 2000 
transfection reagent (Invitrogen, Life Technologies) as previously described (96).  
Transfected HEK293T supernatant was collected at 24 and 48 hour timepoints, 
filtered through 0.45 um nylon syringe filters, and concentrated by 
ultracentrifugation at 18 hours at 8,500RPM at 4oC.  Medium was aspirated and 
pellet was resuspended in 1.2ml total volume and stored at -80oC.  Murine 
retrovirus: 107 293T cells were plated and after 18 hours co-transfected with 20 
ug pNGVL3-g/p, 20 ug pMSCV-RD114, and 40 ug pMMTV CD4 zeta transfer 
vector also using the Lipofectamine 2000 transfection reagent (Invitrogen, Life 
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Technologies).  After 24, 48, and 72 hours, supernatants were harvested, filtered 
through 0.45 um nylon syringe filters, and frozen at -80C.   
 
Cell culture. Purified CD4 and CD8 T lymphocytes were obtained by University 
of Pennsylvania Human Immunology Core/CFAR Immunology Core from de-
identified healthy donors.  T cells were purified by negative selection using the 
RosetteSep Human CD4+ or CD8+ T Cell Enrichment Cocktails according to the 
manufacturer’s protocols (StemCell Technologies). T cells were cultured at 1x106 
per mL in “complete RPMI 1640:”  RPMI 1640 (Life Technologies) supplemented 
(ThermoFisher Scientific) wih 10% fetal calf serum (Seradigm),  1% Penn Strep 
(Life Technologies), 2 mM GlutaMax (Life Technologies), and 25 mM HEPES 
buffer (Life Technologies).  T cells were stimulated with anti-CD3/CD28 coated 
Dynabeads (Life Technologies) at a 3:1 bead to cell ratio and 100-300 IU/mL of 
recombinant human interleukin-2 for 5 days prior to bead removal.  1 day after 
stimulation, 200ul of lentivirus supernatant was added to 0.5x106 cells.  MMLV 
vector transduction was performed on days 3 and 5, with 1ml virus supernatant 
added to a Retronectin (Takara)-coated 24 well plate and spinoculated according 
to the manufacturer’s instructions.  Medium was doubled on day 3 and changed 
completely on day 5, and then added every other day throughout cell culture, or 
as necessary based on cell counts.   
 
In vitro HIV replication control assay and intracellular Gag stain.  Two days 
after removing the anti-CD3/CD28 beads, CD4 T cells were infected with the 
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CCR5-tropic HIV strain Bal, and 24 hours later were co-cultured at varying 
effector to target (E:T) ratios with CAR CD8 T cells.  Bal viral stocks (280ng/ml 
p24) was prepared by harvesting the cell-free supernatant from anti CD3/CD28 
activated CD4 T cells and freezing in aliquots.  Activated CD4 T cells were 
infected by adding approximately 1ml of supernatant per 20 million cells 2-3 days 
after removing beads.  The following day CD4 and CD8 T cells were co-cultured 
at varying E:T ratios and HIV spread was monitored by intracellular p24 Gag with 
the KC57 anti-Gag-RD1 antibody (Beckman Coulter) and the Invitrogen Fix and 
Perm buffers, according the manufacturers’ instructions, gating on a population 
of uninfected cells.  To ensure that the same numbers of CAR+ CD8 T cells were 
being compared, we diluted out populations with higher transduction efficiencies 
by adding in nontransduced T cells until all CAR+ CD8 T cell populations 
matched the population with the lowest CAR or TCR transduction efficiency. 
 
Flow cytometry. CD4 CAR surface expression was monitored with mouse anti 
human CD8-FITC and anti-human CD4 APC antibodies (BD biosciences).  The 
scFv CARs were detected with biotinylated F(ab')2 goat anti-human IgG 
(Jackson) and Streptavidin-PE (BD biosciences).  Cells were visualized on a LSR 
II flow cytometer (BD Biosciences) and analyzed using Flowjo software (Tree 
Star) as previously described (97).  KF11 TCR transduction  efficiency was 
detected with an antibody to the TCR Vβ17 chain, subtracting the background 
Vβ17 signal from the NTD T cells (Fig 2-7 A).   
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In vitro cytotoxicity and cytokine assays.  In vitro killing of K562 targets was 
tested with a 51Cr-release assay. 5x105 target cells were loaded with 50 mCi of 
Na2
51CrO4 (Perkin Elmer) for 90-120 minutes, washed twice and resuspended in 
phenol red-free medium with 5% FBS. NTD, CD4 CAR, or scFv CAR transduced 
T cells (two weeks after initial activation) were co-incubated with loaded YU2 
Env+ K562 target cells for 4 hours at various E:T ratios, and chromium release 
into the supernatant was measured with a MicroBeta2 plate counter (Perkin 
Elmer).  Intracellular cytokine production was measured after co-culturing 
5x105 NTD, CD4 CAR, or scFv CAR transduced CD8 T cells at a 1:1 E:T ratio 
with the various target  K562 cell populations for 6 hours.  Cytokine production 
was detected as previously described (98) using rat anti human IL-2 APC (BD 
biosciences), mouse anti human MIP-1β PerCP Cy5.5 (BD biosciences), mouse 
anti human IFN-γ FITC (BD biosciences), and mouse anti human CD107a PE 
(BD biosciences), along with Invitrogen Fix and Perm buffers.      
 
Vector integration qPCR. Genomic DNA was isolated from transduced CD8 T 
cells with the iPrep™ Purification Instrument (Thermo fisher scientific) and qPCR 
analysis was performed using ABI Taqman technology, with a modified version of 
the previously described assay designed to detect the integrated CD4-zeta 
sequence in genomic DNA (gDNA) (43).  To determine copy number per unit 
DNA, a standard curve was generated consisting of 5 to 106 plasmid copies 
spiked into 200 ng nontransduced control gDNA.  The plasmid copy number in 
the standard curve was verified using digital qPCR with the same CD4-z 
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primer/probe set, and performed on a QuantStudioTM 3D digital PCR instrument 
(Life Technologies).  Each data-point was evaluated in triplicate with a positive Ct 
value and % CV less than 0.95% for all quantifiable values.  To control for the 
quantity of interrogated DNA, a parallel amplification reaction was performed 
using 10 ng gDNA and a primer/probe set specific for a non-transcribed genomic 
sequence upstream of the CDKN1A (p21) gene as previously 
described(99).  These amplification reactions generated a correction factor to 
adjust for calculated versus actual DNA input.  Copies of transgene per cell were 
calculated according to the formula:  [Average copies of transgene(from qPCR)x 
gDNA input Correction Factor/Input gDNA(ng)]x 0.0063 ng gDNA/cell. 
 
HIV prevention humanized mouse model. 6 week old NSG (NOD-
scid IL2Rgnull) mice were obtained from The Jackson Laboratory (JAX) and at 7 
weeks treated with 30mg/kg Busulfan mixed 1:1 with PBS.  24 hours later mice 
were injected via tail vein with 10x106 human lymphocytes in 100ul 0.5% human 
serum albumin in PBS, comprised of 8 million CD4 T cells and 2 million CD8 T 
cells (NTD, BBz, 28z, or MMLV-CD4z transduced with a 50% transduction 
efficiency).  Three weeks later mice were tail vein injected with 15ng HIV Bal 
mixed 1:1 with PBS. Peripheral blood was obtained by retro-orbital bleeding, and 
human CD4 and CAR+ CD8 lymphocyte counts were enumerated using BD lysis 
buffer and BD TruCount tubes as previously described (100), staining with  
mouse anti human CD45 PerCp Cy5.5 (BD Biosciences), mouse anti human 
CD4 BV421 (Biolegend), and mouse anti human CD8α BV711 (Biolegend). 
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HIV treatment humanized mouse model. 5 week old NSG (NOD-scid IL2Rgnull) 
mice were obtained from The Jackson Laboratory (JAX) and at 6 weeks were 
injected with 5 million CD8-depleted human PBMCs, and 12 days later injected 
with 1 million HIV Bal-infected (or mock-infected) autologous CD4 T cells that 
had been in vitro infected with HIV Bal and cultured with ART for 2 days prior to 
freezing.  The same day as HIV infection, mice began receiving 200mg/kg daily 
intraperitoneal injections of the reverse transcriptase inhibitor nucleotide analog 
tenofovir disoproxil fumarate (TDF) for 4 days.  On Day 16, 5 million CD8 T cells 
were injected (NTD, BBz, or 28z).  Peripheral blood was obtained by retro-orbital 
bleeding, and human CD4 and CAR+ CD8 lymphocyte counts were enumerated 
using BD lysis buffer and BD TruCount tubes as previously described (100), 
staining with  mouse anti human CD45 PerCp Cy5.5 (BD Biosciences), mouse 
anti human CD4 BV421 (Biolegend), and mouse anti human CD8α BV711 
(Biolegend). 
 
HIV RNA viral load assay. RNA was extracted from 10-30µl of plasma using 
methods as described (101) and reconstituted in a final volume of 15ul.  Prior to 
extraction, a uniform quantity of Replication Competent Avian Sarcoma (RCAS) 
virus spiked into each plasma sample and amplified separately to verify 
virus/RNA recovery and absence of PCR inhibition (102).  RNA was reverse 
transcribed using random hexamers and quantified by Q-PCR using the 
LightCycler 480 Probes Master (Roche; Indianapolis, IN) on an ABI 7500FAST 
real-time thermocycler using an in vitro transcribed RNA standard.  For each 
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sample, the Q-RT-PCR reaction was run in duplicate on 5ul RNA; no-reverse 
transcriptase reaction and RCAS amplification were run on one well per sample 
using 2.5ul RNA. The HIV-1 primer/probe targets the pol gene and detects all 
group M clades as described in (101), and RCAS amplification used primer/probe 
as described in (102). HIV-1 quantification was normalized to equivalent volumes 
of starting plasma. 
 
Culture supernatant p24 detection.  Culture supernatant was harvested after 7 
days of co-culture and diluted 1:10,000 and analyzed using the commercially 
available p24 ELISA assay kit (Perkin-Elmer).  Assay protein standards ranged 
from 9.4pg/ml to 150pg/ml.   
 
Ultrasensitive p24 detection from mouse plasma.  Plasma was collected by 
centrifugation of the whole blood and diluted according to a protocol supplied by 
Bonnie Howell (Merck & Co, Inc.).  The HIV p24 Gag protein was measured 
using the p24 single molecule array using the Simoa HD-1 Analyzer (Quanterix) 
following the manufacturer’s instructions.  Each sample was measured in 
duplicate and concentration calculated based on a standard curve. The average 
concentration of two replicates for each sample was reported.  The accurate 
detection range was 0.008pg/ml to 39.5pg/ml. 
 
Statistics.  In vitro HIV replication control significance was detected using a 1-
way ANOVA test, stratifying based on the E:T ratio (p values: ns >0.05, *<0.05, 
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**<0.01, ***<0.0001), using the 30:1 E:T ratio for Fig 2-9 A.  All E:T ratios are 
presented in the figures as a single graph due to space limits.  For the mouse 
models, non-parametric distributions were determined and Kruskall Wallis 
analysis was performed and, if overall comparison showed significant 
differences, then Mann Whitney Test was performed for pairwise comparisons 
(as samples were not powered for post-hoc analysis of multiple comparisons) 
and significance results are reported on each figure (p values: ns >0.05, *<0.05, 
**<0.01, ***<0.0001).   
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Figures 
 
 
Figure 2-1. Lentiviral backbone augments CAR expression and control over HIV 
replication.  (A-D) Primary human CD8 T cells were activated with αCD3/αCD28 coated 
beads and were either left (A) nontransduced (NTD), (B) transduced with the original 
MMLV-based CD4 CAR, or (C) transduced with the same CAR placed in a HIV-based 
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lentiviral vector, both driven by the PGK promoter.  After eight days T cells were stained 
for CD4 and CD8 by flow cytometry.  Median fluorescence intensity (MFI) is indicated on 
each graph.  (D) Overlying histograms of the data shown in (A-C). (E) Eight days post 
activation, qPCR was performed and the number of integrated vector copies per cell was 
calculated.  (F) Schematic of experimental design to study the control over HIV 
replication by T cells expressing HIV-specific CARs. Briefly, following activation with 
αCD3/αCD28 coated beads, CD4 T cells were infected with HIV Bal, and 24 hours later 
the indicated CD8 T cells were mixed at the indicated effector to target (E:T) ratios.  
After 7 days of co-culture, the expression of surface CD4, CD8, and intracellular Gag 
was measured by flow cytometry.  (G) Intracellular Gag staining on CD8 negative cells, 
and (H) Intracellular Gag staining on CD8 positive cells.  (I) Summary data for a single 
experiment, performed in triplicate, gating on the CD8 negative cells.  Error bars indicate 
standard error of the mean (SEM).  Significance was detected using a 1-way ANOVA 
test, stratifying based on the E:T ratio (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001).  
This data is representative of three independent experiments.  Fig 2-21 shows each of 
the 3 independent experiments. (J) Measurement of levels of intracellular Gag in CD8 
negative T cells over the time course of an experiment.  Each graph represents a 
different E:T ratio.  Error bars indicate SEM (n=3).   
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Figure 2-2.  Gating strategy to separate the CD8 T cells from the CD4 T cells.  After 
setting up our coculture assay, described in the Fig 2-1 legend, HIV replication is 
measured by staining for intracellular p24 (Gag).  To distinguish between HIV spread 
throughout the CD4 T cells and infection of the CD4 CAR+ CD8 T cells, separate gates 
are drawn on these two populations.  After gating for (A) cell size (FSC versus SSC 
plot), (B) CD8 and CD4 are plotted and two gates are drawn: (D) one encompasses all 
CD8+ cells and will encompass CD8 single positive nontransduced cells or CD4+ CD8+ 
double positive, CAR transduced CD8 T cells.  The other gate (C) is on CD8 negative 
cells, to capture infected cells that have downregulated CD4 as well as CD4 expressing 
cells.   
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Figure 2-3. CD4 CAR Transduced CD8 T cells are not infected by cell-free HIV.  
Primary human CD8 T cells were activated and either left NTD or transduced with an 
optimized CD4 CAR lentiviral expression vector (EF1α promoter, CD8α transmembrane 
domain).  After eight days the cells were either left uninfected, inoculated with 70ng p24 
of HIV Bal by cell-free addition to culture supernatant, or cocultured at varying effector to 
target ratios with CD4 T cells that had been previously infected with the same stock of 
HIV Bal for 24 hours (20ng p24/1x106 CD4 T cells).  After 6 days of culture, cultures 
were collected, and the CD8 T cells were gated on and analyzed for intracellular HIV 
Gag expression. 
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Figure 2-4. EF1α promoter and CD8α transmembrane domains improve CAR 
expression and control over HIV.  (A) Schematic of the constructs compared in this 
figure.  (B) CD4 CAR expression 8 days after activation.  Median fluorescence intensity 
(MFI) is indicated on each graph.  (C) Intracellular Gag staining on day 7 of co-culture, 
for CD8 negative T cells and (D) for CD8 positive T cells.  (E) Summary data for a single 
experiment, performed in triplicate, gating on the CD8 negative cells.  Error bars indicate 
SEM.  Significance was detected using a 1-way ANOVA test, stratifying based on the 
E:T ratio (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001).  This data is representative of 
three independent experiments.  Fig 2-22 shows each of the 3 independent 
experiments. (F) The levels of intracellular Gag in CD8 negative T cells over the time 
course of an experiment.  Each graph represents a different E:T ratio.  Error bars 
indicate SEM (n=3).        
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Figure 2-5. Supernatant HIV Gag p24 ELISA results correlate with intracellular HIV 
Gag p24 staining and flow cytometry.  Using the experimental design described in the 
Fig 2-1 legend, a coculture assay was performed with the indicated CAR+ CD8 T cell 
populations with HIV-infected CD4 T cells.  After 7 days of culture, the intracellular p24 
Gag was measured by flow cytometry and the culture supernatant from the same wells 
was analyzed for p24 Gag by ELISA.  Error bars indicate SEM (n=3).   
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Figure 2-6. Gag staining in CAR+ CD8 T cells is not an artifact of gating on a small 
number of CD8 T cells.  Using the experimental design described in the Fig 2-1 legend, 
a coculture was performed using CD8 T cells either left NTD or transduced with an 
optimized CD4 CAR lentiviral expression vector (EF1α promoter, CD8α transmembrane 
domain).  After 5 days of co-culture, the intracellular Gag was measured by flow 
cytometry, collecting 2 million cells per well to ensure that at the 1:200 dilution, 1x104 
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CD8 T cells would be collected.  The pattern of infection was compared to that seen in 
the same construct used in Fig 2-4 and presented as zebra plots. (A) Shows gating on 
CD8 positive cells and (B) shows gating on CD8 negative cells. 
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Figure 2-7. KF11 TCR-transduced CD8 T cells recognize Gag peptides presented 
by CD4 T cells.  (A) Primary human CD8 T cells were obtained from a HLA-B57+ 
normal donor and activated with αCD3/αCD28 coated beads.  Cells were either left 
nontransduced (NTD)  or transduced to express a HLA-B57 restricted TCR specific for 
KAFSPEVIPMF (KF11).  KF11 TCR transduction efficiency was detected with an 
antibody to the TCR Vβ17 chain, subtracting the background Vβ17 signal from the NTD 
T cells.  (B) Primary human CD8 T cells from a HLA-B57+ T cell donor were activated 
with αCD3/αCD28 coated beads and were either left nontransduced (NTD) or 
transduced with a lentiviral vector expression vector for the KF11 TCR, frozen 8 days 
post activation, and then thawed 48 hours prior to coculture.  Autologous CD4 T cells 
were activated with αCD3/αCD28 coated beads and 11 days post activation 10 million 
cells were electroporated with 40ug of mRNA encoding the HIV Gag or HIV Pol proteins, 
or mock electroporated.  After 24 hours, the NTD or KF11 CD8s were cocultured in at a 
1:3 E:T ratio for 5 hours and IL-2 and TNFα production was measured. 
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Figure 2-8.  Re-directed T cells expressing a CD4 CAR are 100-fold more potent 
than re-directed T cells specific for B57-KF11.   (A)  Gag staining on day 6 of co-
culture for CD8 negative T cells.  (B) Summary data for a single experiment performed in 
triplicate, gating on the CD8 negative T cells.  Error bars indicate SEM.  Significance 
was detected using a 1-way ANOVA test, stratifying based on the E:T ratio (p values: ns 
>0.05, *<0.05, **<0.01, ***<0.0001).  This data is representative of three independent 
experiments.  Fig 2-23 shows each of the 3 independent experiments. 
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Figure 2-9. CD4-based CARs control HIV more effectively than broadly neutralizing 
antibody-based CARs.  (A) Specific lysis of Cr51 labeled K562 target cells expressing 
HIV-1 YU2 GP160.  Significance was detected using a 1-way ANOVA test on the 30:1 
E:T ratio (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001).  Data plotted shows the 
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average of three independent experiments.  Error bars indicate SEM (n=3).  (B) Gag 
staining on day 6 of co-culture for CD8 negative T cells and (C) the CD8 positive T cells.  
The data from the best (PGT128) and one of the worst (PG9) scFv-based CARs are 
compared to the CD4 CAR here, but the complete construct comparison is presented in 
Supplementary Fig. 6.  (D)  Summary data for a single experiment performed in 
triplicate, gating on the CD8 negative cells.  Error bars indicate SEM .  Significance was 
detected using a 1-way ANOVA test, stratifying based on the E:T ratio (p values: ns 
>0.05, *<0.05, **<0.01, ***<0.0001).  Data is representative of three independent 
experiments.  Fig 2-24 shows each of the 3 independent experiments. 
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Figure 2-10. ScFv-based HIV specific CARs produce cytokines as well as CD4-
based CAR do not control HIV replication as well as the CD4 CAR and succumb to 
infection.  (A) Primary human CD8 T cells were activated either left NTD or transduced 
with the indicated CAR vectors.  Two weeks post activation, the CD8 T cells were co-
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cultured for 6 hours at a 1:1 ratio with K562 cells expressing HIV-1 YU2 GP160, and 
intracellular IFNγ and MIP-1β production was measured.  Transduction efficiencies were 
normalized to 60% prior to co-culture.  (B)  Using the experimental design summarized 
in Fig 1, the HIV-specific CARs were tested for their ability to control HIV-1 replication in 
primary human CD4 T cells.  NTD, GFP transduced, and CD19-zeta CAR transduced 
CD8 T cell treatments were included as controls.  After 6 days of co-culture, intracellular 
Gag and CD4 staining is shown for CD8 negative T cells.  (C) Shows gating on the CD8 
positive cells. 
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Figure 2-11. ICOS, CD27, and 4-1BB costimulation impair control of HIV replication 
in vitro.  (A) Gag staining on day 9 of co-culture for CD8 negative T cells. (B)  Summary 
data for a single experiment performed in triplicate, gated on the CD8 negative T cells.  
Error bars indicate SEM.  Significance was detected using a 1-way ANOVA test, 
stratifying based on the E:T ratio (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001).  Data 
is representative of three independent experiments.  Fig 2-25 shows each of the 3 
independent experiments. 
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Figure 2-12. HLA-DR expression histogram.  K562 cells transduced with vectors 
encoding the HLA-DR*0401 α and β chains and single-clone sorted on high expressing 
cells, were stained for HLA-DR expression along with K562 control cells that had been 
transduced with HLA-A2, and the MHC class II highly expressing Raji B cells.   
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Figure 2-13. CD4 CARs respond to Env+ cells and not MHC class II+ cells.  (A) 
Primary human CD8 T cells were activated with either left NTD or transduced with the 
indicated CD4 CARs.  Two weeks post activation, the CD8 T cells were co-cultured for 6 
hours at a 1:1 ratio with unmodified K562 cells, K562 cells expressing high levels of 
HLA-DR, or K562 cells expressing HIV-1 YU2 GP160.  Intracellular IFNγ and MIP-1β 
expression is shown on the left, and intracellular IL-2 expression and CD107a surface 
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mobilization is shown on the right.  (B) A co-culture assay was designed to demonstrate 
that CD4 CAR+ CD8 T cells do not kill MHC class II-expressing target cells.  Briefly, NTD 
or CD4 28z CAR transduced CD8 T cells from (A) were co-cultured with K562 cells 
expressing both HLA-A2 and GFP as well as K562 expressing both HLA-DR*0401 and 
mCherry at a 1:1:1 ratio.  Flow cytometry measuring GFP and mCherry expression was 
performed immediately after mixing (0 hr) and after 3 days of co-culture (72 hr).  C) 
Summary data for a single experiment performed in triplicate, measuring the ratio of 
HLA-A2/GFP-expressing cells to HLA-DR*0401/mCherry-expressing cells after 24, 48, 
and 72 hours of culture.  Error bars indicate SEM.  Data is representative of three 
independent experiments.   
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Figure 2-14. Optimized CAR T cells control HIV-1 replication better and expand to 
greater levels in vivo than first generation CAR T cells.  Cohorts of NSG mice were 
infused with 8 million human CD4 T cells and 2 million human CD8 T cells (50% CAR 
transduction efficiency).  CD8 T cells were either left NTD, transduced with optimized 
CD4 CARs containing either 4-1BB or CD28 intracellular costimulatory domains, or the 
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clinical trial, MMLV-based CAR, denoted in as NTD, BBz, 28z, and MMLV-CD4z, 
respectively.  Three weeks post injection, engraftment was measured to determine (A) 
baseline peripheral CD4 T cell counts and (C) baseline CAR+ CD8 T cell counts.  Two 
days later mice were infected with HIV-1 Bal via tail vein injection.  22 days post 
infection, (B) endpoint peripheral CD4 T cell counts and (D) CAR+ CD8 T cell counts 
were obtained.  (E) Seven and (F) eighteen days post infection mice were bled and HIV 
RNA copies per μl plasma were determined by qPCR and normalized to CD4 T cell 
counts.  Mann Whitney Test was used to determine statistical significance (p values: ns 
>0.05, *<0.05, **<0.01, ***<0.0001). 
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Fig 2-15. HIV treatment model timeline.  NSG (NOD-scid IL2Rgnull) mice were injected 
with 5 million CD8-depleted human PBMCs, and 12 days later injected with 1 million HIV 
Bal-infected (or mock-infected) autologous CD4 T cells.  For four days the infected mice 
were injected intraperitoneally with 200mg/kg of the reverse transcriptase inhibitor 
nucleotide analog tenofovir disoproxil fumarate (TDF) to prevent HIV viremia.  Mice were 
bled on day 15 to analyze pre-CD8 human cell counts and measure plasma HIV RNA.  
On Day 16, 5 million CD8 T cells were injected that were either nontransduced or 
transduced with optimized CD4-zeta CARs containing either 4-1BB or CD28 intracellular 
costimulatory domains.  CD8 T cell transduction efficiencies were normalized to 55% 
prior to injection into mice.  Mice were bled on day 26 and 34.  For logistical reasons the 
mice had to be terminated in two groups, with BBz mice terminated on day 37 and the 
NTD and 28z terminated on day 40. 
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Figure 2-16. CAR T cells containing 4-1BB outperform CAR T cells containing 
CD28 in a humanized mouse HIV-treatment model.  The experimental timeline and 
detailed description is provided in Fig 2-15.  CD4 T cell counts are shown (A) 3 days 
post ART initiation, prior to CD8 T cell injection (B) 18 days post ART removal and (C) at 
the endpoint termination bleeds (21 or 24 days post ART removal).  For logistical 
reasons the mice had to be terminated in two groups, with BBz mice terminated 21 days 
post ART removal and the NTD and 28z terminated 24 days post ART removal.  CD8 T 
cell counts are shown (D) 10 days post ART removal and CD8 T cell injection (E) 18 
days post ART removal and (F) at the endpoint termination bleeds (21 or 24 days post 
ART removal).  HIV RNA copies per μl plasma were determined by qPCR and 
normalized to CD4 T cell counts (G) 10 days post ART removal (H) 18 days post ART 
removal and (I) the endpoint bleed.  Mann Whitney Test was used to determine 
statistical significance (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001). 
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Fig 2-17.  CD4 and CD8 T cell counts for mock infected NSG mice used in the HIV 
treatment model.  (A-C) CD4 T cell counts for the mock-infected (HIV-free) components 
of the mouse cohorts described in the Fig 8 legend and shown in Fig 7A-C, (A) 3 days 
post mock infection, (B) 3 weeks post mock infection, and (C) endpoint.  (D-F) CD8 T 
cell counts for the mock-infected (HIV-free) components of the mouse cohorts described 
in the Fig 8 legend and shown in Fig 7D-F, (D) 2 weeks post mock infection, (E) 3 weeks 
post mock infection, and (F) endpoint.  Mann Whitney Test was used to determine 
statistical significance (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001). (G) Table of the 
median CD4 T cell counts at the different timepoints measured for both HIV infected and 
mock infected groups. 
 
 
 
68 
 
 
Fig 2-18.  Measures of HIV p24 Gag protein levels in plasma as detected by 
ultrasensitive p24 ELISA.  Plasma was isolated from whole blood by centrifugation and 
diluted according to a protocol supplied by Bonnie Howell (Merck & Co, Inc.) and the HIV 
p24 Gag protein was measured p24 single molecule array using the Simoa HD-1 
Analyzer.  Values displayed are femtograms p24 per μl plasma normalized to CD4 T cell 
counts (A) 10 days post ART removal and (B) the endpoint bleeds, 21 or 24 days post 
ART removal.  Mann Whitney Test was used to determine statistical significance (p 
values: ns >0.05, *<0.05, **<0.01, ***<0.0001). 
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Fig 2-19. Summary of improvements made to original clinical trial vector.  (A) 
Table and schematic depicting the complete list of modifications explored to improve the 
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original clinical trial, MMLV-based construct.  (B) Using the experimental design 
summarized in Fig 1E, primary human CD8 T cells were activated with αCD3/αCD28 
coated beads and were either left nontransduced (NTD), transduced with the original 
MMLV-based CD4 based CAR driven by the PGK promoter (clinical trial CAR), or 
transduced the optimized EF1α-CD8α TM CAR, placed in a HIV-based lentiviral vector.  
Transduction efficiencies were normalized to 60% prior to co-culture.  After 7 days of co-
culture with HIV Bal-infected CD4 T cells, the expression of surface CD4 and 
intracellular Gag p24 was measured by flow cytometry, gating on CD8 negative T cells. 
(C) Shows gating on the CD8 positive cells.  (D) Summary data for a single experiment 
performed in triplicate, gating on the CD8 negative cells.  Error bars indicate SEM (n=3).  
Significance was detected using a 1-way ANOVA test, stratifying based on the E:T ratio 
(p values: ns >0.05, *<0.05, **<0.01, ***<0.0001).  This data is representative of three 
independent experiments.   
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Optimized CD4 CARs: 
CD4 CD28 CD3-zeta sequence: 
MNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHW
KNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYIC
EVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQ
GGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFQKASSIVYKKEGEQ
VEFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKNKEVSVKRVTQDPKL
QMGKKLPLHLTLPQALPQYAGSGNLTLALEAKTGKLHQEVNLVVMRATQLQKN
LTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWVLNPEAGMWQCLLSDSGQ
VLLESNIKVLPTWSTPVQPSGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV
HTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMT
PRRPGPTRKHYQPYAPPRDFAAYRSIDRVKFSRSADAPAYQQGQNQLYNELNLG
RREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGE
RRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 
Yellow – CD4 EC domain 
Turqoise – CD8α hinge 
Red – CD28 TM and ICD 
Green  - CD3 zeta 
 
CD4 4-1BB CD3-zeta sequence: 
MNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHW
KNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYIC
EVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQ
GGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFQKASSIVYKKEGEQ
VEFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKNKEVSVKRVTQDPKL
QMGKKLPLHLTLPQALPQYAGSGNLTLALEAKTGKLHQEVNLVVMRATQLQKN
LTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWVLNPEAGMWQCLLSDSGQ
VLLESNIKVLPTWSTPVQPSGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV
HTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQT
TQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG
HDGLYQGLSTATKDTYDALHMQALPPR 
Yellow – CD4 EC domain 
Turqoise – CD8α hinge  
Pink  - CD8α TM 
Red – 4-1BB ICD 
Green  - CD3 zeta 
 
 
 
Antibody Based CARs 
 
PG9 CD3-zeta sequence: 
QRLVESGGGVVQPGSSLRLSCAASGFDFSRQGMHWVRQAPGQGLEWVAFIKYD
GSEKYHADSVWGRLSISRDNSKDTLYLQMNSLRVEDTATYFCVREAGGPDYRN
GYNYYDFYDGYYNYHYMDVWGKGTTVTVSSGGGGSGGGGSGGGGSQSALTQ
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PASVSGSPGQSITISCNGTSNDVGGYESVSWYQQHPGKAPKVVIYDVSKRPSGVS
NRFSGSKSGNTASLTISGLQAEDEGDYYCKSLTSTRRRVFGTGTKLTVLSGTTTP
APRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLL
LSLVITLYCRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPE
MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTA
TKDTYDALHMQALPPR 
 
PGT128 CD3-zeta sequence: 
QSALTQPPSASGSPGQSITISCTGTSNNFVSWYQQHAGKAPKLVIYDVNKRPSGV
PDRFSGSKSGNTASLTVSGLQTDDEAVYYCGSLVGNWDVIFGGGTKLTVLGGSS
RSSSSGGGGSGGGGQPQLQESGPTLVEASETLSLTCAVSGDSTAACNSFWGWVR
QPPGKGLEWVGSLSHCASYWNRGWTYHNPSLKSRLTLALDTPKNLVFLKLNSV
TAADTATYYCARFGGEVLRYTDWPKPAWVDLWGRGTLVTVSSSGTTTPAPRPP
TPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVI
TLYCRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP
RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTY
DALHMQALPPRR 
 
VRC01 CD3-zeta sequence: 
EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIP
DRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIKRGGSSRSSS
SGGGGSGGGGQVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKR
PEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFC
TRGKNCDYNWDFEHWGRGTPVIVSSSGTTTPAPRPPTPAPTIASQPLSLRPEACRP
AAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCRVKFSRSADAPAYQ
QGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK
MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 
 
3BNC60 CD3-zeta sequence: 
DIQMTQSPSSLSARVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKLERGV
PARFSGRRWGQEYNLTINNLQPEDVATYFCQVYEFIVPGTRLDLKGGSSRSSSSG
GGGSGGGGQVHLSQSGAAVTKPGASVRVSCEASGYKISDHFIHWWRQAPGQGL
QWVGWINPKTGQPNNPRQFQGRVSLTRQASWDFDTYSFYMDLKAVRSDDTAIY
FCARQRSDFWDFDVWGSGTQVTVSSSGTTTPAPRPPTPAPTIASQPLSLRPEACRP
AAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCRVKFSRSADAPAYQ
QGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK
MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 
 
PGDM1400 CD3-zeta sequence: 
DFVLTQSPHSLSVTPGESASISCKSSHSLIHGDRNNYLAWYVQKPGRSPQLLIYLA
SSRASGVPDRFSGSGSDKDFTLKISRVETEDVGTYYCMQGRESPWTFGQGTKVDI
KGGSSRSSSSGGGGSGGGGQAQLVQSGPEVRKPGTSVKVSCKAPGNTLKTYDLH
WVRSVPGQGLQWMGWISHEGDKKVIVERFKAKVTIDWDRSTNTAYLQLSGLTS
GDTAVYYCAKGSKHRLRDYALYDDDGALNWAVDVDYLSNLEFWGQGTAVTV
SSSGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL
AGTCGVLLLSLVITLYCRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK
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RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGL
YQGLSTATKDTYDALHMQALPPR 
Yellow – ScFv EC domain 
Turqoise – CD8α hinge  
Pink  - CD8α TM 
Green  - CD3 zeta 
 
 
Fig 2-20. Annotated Sequence Files for Optimized CD4 CARs and Antibody Based 
CARs. 
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Figure 2-21. Triplicate experiments demonstrating that a lentiviral backbone 
augments CD4 CAR expression and control over HIV replication.  The same 
experimental setup (as described in the Fig 2-1 legend) was performed in triplicate and 
intracellular HIV Gag is shown at the peaks of HIV replication for three independent 
donors, gating on the CD8 negative cells.  Error bars indicate SEM (n=3).  Significance 
was detected using a 1-way ANOVA test, stratifying based on the E:T ratio (p values: ns 
>0.05, *<0.05, **<0.01, ***<0.0001). 
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Figure 2-22. Triplicate experiments demonstrating that the EF1α promoter and 
CD8α transmembrane domains improve CAR expression and control over HIV-1.  
The same experimental setup (as described in the Fig 2-4 legend) was performed in 
triplicate and intracellular HIV Gag is shown at the peaks of HIV replication for three 
independent donors, gating on the CD8 negative cells.  Error bars indicate SEM (n=3).  
Significance was detected using a 1-way ANOVA test, stratifying based on the E:T ratio 
(p values: ns >0.05, *<0.05, **<0.01, ***<0.0001). 
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Fig 2-23.  Triplicate experiments demonstrating that the CD4 CAR is over 100-fold 
more potent than HIV-specific elite controller TCR in vitro.  The same experimental 
setup (as described in the Fig 2-8 legend) was performed in triplicate and intracellular 
HIV Gag is shown at the peaks of HIV replication for three independent donors, gating 
on the CD8 negative cells.  Error bars indicate SEM (n=3).  Significance was detected 
using a 1-way ANOVA test, stratifying based on the E:T ratio (p values: ns >0.05, 
*<0.05, **<0.01, ***<0.0001). 
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Fig 2-24.  Triplicate experiments demonstrating that the CD4 CAR controls HIV-1 
more effectively than broadly neutralizing antibody based CARs.  The same 
experimental setup (as described in the Fig 2-9 legend) was performed in triplicate and 
intracellular HIV Gag is shown at the peaks of HIV replication for three independent 
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donors, gating on the CD8 negative cells.  Error bars indicate SEM (n=3).  Significance 
was detected using a 1-way ANOVA test, stratifying based on the E:T ratio (p values: ns 
>0.05, *<0.05, **<0.01, ***<0.0001). 
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Fig 2-25.  Triplicate experiments demonstrating that CD28 and 4-1BB 
costimulation have opposing effects on the control of HIV-1 replication in vitro.  
The same experimental setup (as described in the Fig 2-11 legend) was performed in 
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triplicate and intracellular HIV Gag is shown at the peaks of HIV replication for three 
independent donors, gating on the CD8 negative cells.  Error bars indicate SEM (n=3).  
Significance was detected using a 1-way ANOVA test, stratifying based on the E:T ratio 
(p values: ns >0.05, *<0.05, **<0.01, ***<0.0001). 
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Table 2-1.  Copies of HIV RNA per μl plasma normalized to CD4 T cell counts while 
on ART.  Mice were injected with 1 million HIV-infected CD4 T cells (See Fig 2-15 for 
timeline) and given daily intraperitoneal injections (200mg/kg) of the reverse 
transcriptase inhibitor nucleotide analog tenofovir disoproxil fumarate (TDF) for 3 days 
and then bled for viral load detection.  HIV RNA copies per μl plasma were determined 
by qPCR and normalized to CD4 T cell counts. 
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CHAPTER 3 – Protecting CAR-Transduced CD8 T Cells from HIV Infection 
 
Parts of this chapter were previously published in: 
 
R. S. Leibman, J. L. Riley, Engineering T Cells to Functionally Cure HIV-1 
Infection. Molecular therapy : the journal of the American Society of Gene 
Therapy 23, 1149-1159 (2015). 
 
Protecting CD4 CAR+ T lymphocytes from HIV entry 
 
As demonstrated in Chapter 2, expression of the CD4 CAR promotes 
HIV-infection of CAR+ CD8 T cells when diluted to low E:T ratios.  At such ratios, 
the CD8 T cells lose control over HIV replication and the virus is free to spread 
among the CD4 T cells in coculture.  Therefore, HIV infection appears to limit 
CAR T cell functionality, and we suspect that preventing infection of these cells 
will further augment their ability to control HIV. 
Prior to this dissertation project, much effort has been spent by others on 
identifying methods to protect CD4 T cells from HIV infection (to be discussed in 
detail below).  The selective advantage of HIV-resistant CD4 T cells allows for 
expansion in the presence of the virus, due to cytotoxicity to the unprotected CD4 
T cells.  Preserved key CD4 T-helper cells could then potentially boost CD8 T 
cell responses to restore functional CTL control in vivo.  Reducing expression of 
the CD4 receptor for HIV and the equally required CCR5 or CXCR4 coreceptors 
has been explored as a method to prevent infection of host cells.  While deleting 
CD4 expression is not a viable therapeutic option because of its necessary 
functions, strategies that disrupt coreceptor expression or block the virus-
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coreceptor interaction are feasible and have been explored clinically(88, 103, 
104). 
 
Fusion inhibitors 
 
Peptides derived from the C-terminus of the GP41 domain of Env (C-
peptides) can be utilized to prevent the fusion of the virion with the host cell 
membrane (105).  C-peptides interact with the viral GP41 N-terminus to disrupt 
six-helix bundle formation, which contains the energy required for fusion.  
Membrane-anchored C-peptides block HIV infection in vitro when expressed 
from retroviral or lentiviral vectors (106, 107).  Perez and colleagues showed a 
15-fold reduction in HIV replication when C-peptide transduced primary CD4 T 
cells were challenged with the highly virulent BK132 strain of HIV (106).   
Resistance mutations to both soluble and membrane bound forms of the C-
peptide-based inhibitor T-20/Enfurvertide did not result in insensitivity to an 
optimized C-peptide vector, termed M87o, which included 10 additional amino 
acids than T-20 (108).  Partial resistance to M87o could be forced after repeated 
passaging of HIV on cells expressing sub-optimal expression vectors and was 
accompanied by a complex pattern of mutations in both GP120 and GP41 
regions of Env (109).  M87o-transduced cells were given to 10 patients with drug-
resistant HIV infection and advanced disease (103).  Gene-modified cells were 
detected at one year post-infusion in both lymph nodes and peripheral cells, and 
CD4 T cell counts increased significantly from baseline.  Four out of seven 
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patients who altered their antiretroviral therapy regiments four months into the 
trial experienced over a log decline in plasma virus, and the patients who 
remained viremic throughout the study had the best persistence of gene modified 
cells at one year post infusion.  As these therapeutic peptide sequences are 
virally derived and overlap with GP41 sequences known to be bound by human 
antibodies, they have the potential to trigger immune-mediated deletion.  
Therefore, a modified peptide was more recently designed to remove potential 
MHC-I and antibody recognition epitopes while retaining antiviral efficacy (110).   
Recently, Leslie et al. demonstrated potent inhibition of HIV using a 34 
amino acid peptide from the HR2 region of GP41, termed C34, fused to the 
sequence of the CXCR4 coreceptor (87).  CD4 T cells transduced with a lentiviral 
vector to stably express the C34-CXCR4 fusion protein trans-dominantly inhibited 
both CCR5- and CXCR4-utilizing strains of HIV.  Importantly, viruses that were 
resistant to enfuvirtide (a soluble HR2-derived peptide) remained susceptible to 
C34-CXCR4, and these transduced cells enriched in humanized mice relative to 
untransduced control T cells.  Based on these promising results the University of 
Pennsylvania is sponsoring a single cohort, open-label phase I trial, currently 
open to enrollment (NCT03020524). 
 
Coreceptor editing 
 
The discovery that people who lacked functional CCR5 were both healthy 
and resistant to CCR5-tropic strains of HIV prompted researchers to recreate this 
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phenotype with methods designed to disrupt the CCR5 gene loci.  A naturally 
occurring 32 base pair mutation (Δ32) in the second extracellular loop of CCR5 
leads to a translational frameshift and subsequent protein truncation, resulting in 
a non-functional receptor not amenable to HIV fusion (111, 112).  With an allele 
frequency of approximately 10% in Caucasians (although more commonly found 
in people of Western European descent), the majority of the population lacks this 
non-functional CCR5 allele (113-115).  This HIV-resistant phenotype has been 
successfully transferred in the only known case of an HIV cure, in which an HIV-
infected patient with acute myeloid leukemia received an allogeneic 
hematopoietic stem cell transplant (HSCT) from a Δ32 homozygous donor and 
was determined to be virus-free more than three years after discontinuing 
antiretroviral therapy (116, 117).   While this case resulted in a successful cure of 
HIV, HSCT carries too many risks to be considered as anything but a last-line 
treatment option, particularly when the low likelihood of finding a Δ32 HLA-
matched donor is considered.  In contrast, gene modification of autologous cells 
attempts to phenocopy this effect while bypassing the requirement for ablative 
conditioning and finding an HLA matched, HIV-resistant donor.  The overall goal 
is to engineer a population of HIV-resistant cells that could expand in the 
presence of replicating virus due to their selective advantage.  With enough HIV-
resistant cells present, patients could theoretically be taken off ART without 
detrimental levels of CD4 T cell depletion and progression to AIDS.  Over time, 
the reservoirs could, in theory, decrease if HIV was unable to spread due to 
coreceptor knockout.    
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Many coreceptor knockdown strategies have been tested in primary T 
cells or T cell lines including RNAi, antisense RNA, ribozymes, intrabodies, and 
intrakines(118-126).  Various degrees of inhibition were observed with these 
methods that work by decreasing coreceptor expression at the transcript or 
protein levels.  However, knocking out the gene loci for the coreceptors ablates 
expression at the source.  This can be achieved with customizable, gene editing 
technologies including zinc finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs), and CRISPRs (clustered regularly interspaced 
short palindromic repeats).  
 
Coreceptor disruption with zinc finger nucleases  
 
ZFNs are customizable, hybrid restriction enzymes that fuse the FokI 
endonuclease to DNA-binding zinc finger domains.  Amino acid modifications in 
the zinc fingers alter DNA binding specificity, particularly when multiple zinc 
fingers are combined and can be selected with phage display (127, 128).  ZFNs 
are designed in pairs that bind a precise genomic locus in a bidirectional manner 
to dimerize the FokI domains with the correct orientation and spacing required for 
cleavage (129).  This directs the indiscriminate FokI cleavage domain to induce 
dsDNA breaks into the desired target sequence, which can lead to gene 
knockout by error-prone non-homologous end joining (NHEJ) or gene insertion 
by homologous recombination (HR), provided that a homologous substrate is 
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introduced along with the ZFNs (130, 131).  Utilizing two unique ZFNs that are 
active as heterodimers promotes sequence specificity, but also introduces the 
possibility that each of the individual ZFNs will homodimerize and cleave off-
target genomic loci.  Thus, design modifications should be incorporated to ensure 
ZFNs function as obligate heterodimers (104).  An attractive aspect of ZFNs is 
that they can be transiently added to cells as transcripts, proteins, or non-
integrating vectors to avoid the safety concerns associated with integrating viral 
vectors, namely insertional mutagenesis (132).  The permanent and heritable 
nature of gene disruption allows for long-term therapeutic benefit to be achieved 
from short-term ZFN expression.   
 
Perez and colleagues employed an adenoviral (Ad5/35) non-integrating 
vector to deliver ZFNs targeting CCR5 loci to primary human CD4 T lymphocytes 
(83).  The ZFN pair recognized a 24 base pair site within the first transmembrane 
domain of CCR5.  Sequence analysis of the CCR5 target site revealed a 5 base 
pair duplication of the spacer between the ZFN binding sites that occurred in over 
30% of the mutated sequences and introduced an early stop codon within the 
first transmembrane domain of CCR5.  In vitro analysis of primary CD4 T cells 
revealed that 33% of CCR5 disrupted cells were homozygous prior to expanding 
in an HIV-infected environment.  Ultra-deep pyrosequencing was used to detect 
off-target cleavage in the 15 potential sites determined by systematic evolution of 
ligands by exponential enrichment (SELEX), and a small frequency of off-target 
disruption was identified in the CCR2 locus (4% of CCR2 alleles modified 
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compared to 36% of CCR5 alleles modified), which is located near CCR5 on the 
same chromosome and has a single nucleotide difference in the sequence 
targeted by each of the ZFNs.  While CCR2 is important for monocyte trafficking, 
CCR2-/- mice develop without overt signs of physical or immune impairment, so 
it is likely that deletion of CCR2 alleles in a small proportion of lymphocytes 
would not lead to noticeable defects.  In vivo studies using an immunodeficient 
NOD/Shi-scid/IL-2Rγnull (NSG) mouse model of HIV infection resulted in three-
fold enrichment of ZFN modified cells in infected mice relative to uninfected 
controls, one month post infection (83).  Fifty days post infection, the majority of 
mice had more than 50% of their CCR5 alleles disrupted and a 0.72 log reduction 
in plasma viremia.  Over time, CD4 counts increased in ZFN treated mice relative 
to controls.  Yi et al. used an alternative method to deliver CCR5 ZFNs via a non-
integrating lentiviral vector pseudotyped with Envelope from the CXCR4-tropic 
HIV strain LAI, in order to selectively transduce CD4 cells within a culture of 
unstimulated or PHA stimulated primary PBMCs (133).  Reduced viral loads and 
preserved CD4 T cells were observed in NSG mice engrafted with transduced 
PBMCs from HIV-infected patients with either high or suppressed viral loads.   
 
Although CCR5 can be considered the primary HIV coreceptor and is 
required by most viruses during early infection stages, viruses can gain the ability 
to utilize CXCR4, and this is associated with increased disease progression (134-
136).  Thus, to fully protect cells from HIV-infection, strategies should aim to 
disrupt both CXCR4 and CCR5 expression.  ZFNs targeting the second 
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extracellular loop of CXCR4 were employed in a NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
(NSG) mouse model of HIV infection and did not appear to impact trafficking, as 
CXCR4 disrupted cells were found in equal proportions in the blood and spleen 
(137).  A caveat is that trafficking in a humanized mouse model does not entirely 
reflect the conditions in a human or non-human primate.  Protective effects were 
not seen when mice were challenged with the X4-tropic HIV BK132 strain, as the 
virus mutated in vivo to gain the capacity for CCR5-mediated entry.  In another 
NSG mouse study using CXCR4-targeted ZFNs, better control over HIV 
replication was seen when the X4-tropic HIV strain NL4-3 was used, and this was 
accompanied by concomitant increases in CD4 T cell count (138).  A subsequent 
comparison of dual ZFN-treated primary CD4 T cells established that CCR5 and 
CXCR4 could be knocked out in the same cell (139).  Deep sequencing analysis 
of predicted off-target sites failed to detect modification of these non-target sites, 
suggesting that if cross-heterodimerization between CCR5 and CXCR4 targeted 
ZFNs occurs it does not result in mutation of additional loci.  ZFN treated NSG 
mice were then challenged with a combination of HIV Bal and BK132 strains, and 
dual-ZFN treated mice had higher CD4 T cell counts than mice given 
untransduced cells or cells treated with ZFNs that solely targeted CCR5.  Over 
time, the proportion of coreceptor-negative cells increased.   
 
Clinical feasibility of CCR5 ZFNs was demonstrated in a study that reliably 
generated populations of more than 1010 ZFN treated CD4 T cells from HIV-
infected donors, upon stimulation with anti-CD3 and anti-CD28 coated beads 
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(140).  Analysis of expanded ZFN transduced cells revealed that these cells 
retained similar phenotypes, cytokine production levels, and TCR diversity.  
Karyotype analysis detected no chromosomal abnormalities, which might result 
from the high proportion of ZFN induced dsDNA breaks.  Three clinical trials 
using transduced T cells have been performed with these CCR5 ZFNs led by the 
University of Pennsylvania (NCT00842634) and Sangamo Biosciences 
(NCT01252641 and NCT01044654).  The results of NCT00842634, in which 12 
patients received ten billion autologous, modified CD4 T lymphocytes (SB-728) 
were recently published by Tebas and colleagues (88).  The gene modified cells 
could be detected in all patients throughout the duration of the study up for 42 
months, with a median half-life of 64 weeks, and trafficking to the rectal mucosa 
was observed.  Four out of the six patients who   underwent a structured 
treatment interruption (STI) completed the 12 week interruption, during which the 
viral load decreased by an average of 1.2 logs.  One patient’s viral load 
decreased to undetectable levels during STI, and it was later determined that this 
patient was heterozygous for the CCR5 Δ32 mutation.  During the STI, the 
decline of CCR5 modified cells was significantly less than the unmodified cells.  
The rates of HIV DNA decay were found to be 10 times as rapid for SB-728-
treated patients who maintained suppressed viremia (did not undergo STI) 
compared to control aviremic patients who did not receive ZFN-modified cells. 
 
While safety has been demonstrated in these trials, extensive in vitro 
characterization identified over a dozen sites (besides CCR2) in human genome 
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to which the CCR5 ZFNs had enzymatic activity towards (141, 142) .  Notably, 
Pattanayak and colleagues found ZFN-mediated cleavage in the promoter of the 
BTBD10 gene, and downregulation of this gene has been associated with 
malignancy and pancreatic beta-cell apoptosis (141).  However, these studies 
also demonstrated that decreasing the concentration and DNA binding affinity of 
the ZFNs can reduce off-target cleavage activity.  Nevertheless, the possibility 
exists for the dsDNA breaks to induce transformation, whether through gene 
knock out or chromosomal translocations (141, 143). 
 
A similar CCR5 knockout approach was taken with the designer restriction 
enzymes known as transcription activator-like effector nucleases (TALENs) (144, 
145).  TALE DNA binding proteins from the plant pathogens Xanthamonas sp. 
can be fused to the FokI endonuclease, as done for ZFNs, to promote site-
specific cleavage (145).  While ZFNs recognize three nucleotides per zinc finger 
domain (comprised of 30 amino acids), TALENs recognize a single nucleotide 
per 34 amino acids.  Side by side comparisons of ZFNs and TALENs were 
performed in 293T cells and comparable CCR5 disruption frequencies were 
obtained.  TALENs had restricted CCR2 cleavage and a two-fold increase in cell 
survival compared to ZFNs (144, 146).  As off-target effects vary in different cell 
types due to structural differences in chromatin, an important safety assessment 
of ZFNs and TALENs should include an analogous comparison in primary human 
CD4 T cells, the target cell employed in human clinical trials.   
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Coreceptor disruption with CRISPR  
 
The CRISPR system was adapted for eukaryotic genome engineering 
from bacteria and archaea, in which it functions as a prokaryotic immune system.  
Foreign DNA sequences are incorporated as spacers between the CRISPR 
repetitive DNA elements and subsequently transcribed and processed into a 
CRISPR-RNA (crRNA).  The crRNA forms a complex with CRISPR-associated 
(Cas) nuclease proteins that digest invading sequences complementary to the 
crRNA.  For eukaryotic gene editing applications, a type II CRISPR system was 
adapted from Streptococcus pyogenes that only requires two components to 
function: a guide RNA (gRNA) complementary to the target genomic site and its 
associated Cas9 nuclease (147).  Similar to ZFN-mediated cleavage, Cas9 
leaves a dsDNA break that can be repaired by NHEJ or HR.  An attractive 
feature of this system is that only the gRNA must be altered to adapt it to a 
particular genomic site of interest, making it an inexpensive and simple 
procedure.  Moreover, multiple gRNAs can be introduced to simultaneously 
target multiple loci within the same cell.  The only target sequence requirement is 
that it be followed by a protospacer adjacent motif (PAM) “NGG” sequence.  
Cradick and colleagues designed CCR5-specific gRNAs to assess gene editing 
frequencies and off-target effects in 293T cells (148).  CCR2 cleavage was seen 
at a low frequency in this system, even when two nucleotide mismatches existed.  
Additional work has demonstrated that Cas9 tolerates mismatches between the 
gRNA and target DNA, depending on the dose of gRNA administered and the 
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number and location of mismatches (149, 150).  However, a different study 
utilizing CCR5 gRNAs was able to eliminate CCR5 expression in 68% of 
transduced TZM.bl cells, without any detectable off-target cleavage at the highly 
homologous sites identified by bioinformatics screening (88).      
 
Success of coreceptor editing strategies is contingent on generating 
homozygous knockout cells, as demonstrated by the viral load reduction in the 
Δ32 heterozygote patient whose cells received CCR5-directed ZFNs (88).  Which 
method becomes the more useful clinical tool will depend foremost on safety, 
followed by efficacy as well as economic and engineering considerations.  
Bioinformatic software is readily accessible for researchers to identify off-target 
sites where designer endonucleases may cleave, but in vitro and in vivo pre-
clinical testing must follow to verify the results and demonstrate safety(151-154).  
Additionally, nickase versions of ZFNs and Cas9 have been designed to promote 
HR while avoiding the potentially detrimental effects of NHEJ(155, 156).  Using a 
pair of Cas9 nickases with two gRNAs that bind close on the chromosome may 
facilitate genome editing in a manner more analogous to ZFNs and TALENs and 
reduce off-target effects to comparable levels (157).  Unlike the FokI 
endonuclease, Cas9 does not require dimerization for functional enzymatic 
activity, so fusions of catalytically inactive Cas9 and active FokI have been 
designed to impart dimerization requirements on Cas9 while maintaining gRNA 
specificity (158, 159).  Analysis of off-target modifications in human genomic 
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DNA sites introduced by the FokI-Cas9 chimeras showed 140-fold and 8-fold 
reduction relative to WT Cas9 or Cas9 nickases, respectively (159). 
 
Protecting CAR T cells 
 
As described above, the survival benefits afforded by gene editing the 
CCR5 HIV coreceptor using ZFNs or by utilizing GP41-based fusion inhibitors 
had previously been demonstrated in primary human CD4 T cells (83, 87, 88, 
106).  Since we showed in Chapter 2 that the CD4 CAR mediates infection into 
CD8 T cells expressing this construct and this appears to reduce CAR T cell 
functionality and control over HIV, a natural question to ask is whether protected 
CAR T cells control HIV better and enrich in the presence of HIV compared to 
unprotected CAR T cells.  
 A handful of groups have recently undertaken efforts to prevent infection 
and augment CD4 CAR CD8 T cell functionality by means of coreceptor editing 
and fusion inhibitors.  Maclean et al. reported greater specific lysis towards Env+ 
283T cells with rhesus T cells dually transduced to express both an MMLV-based 
CD4 CAR and a membrane-bound form of the GP41 derived C46 peptide (160).  
Kamata et al. used a CD4-zeta CAR vector that also encoded shRNAs to CCR5 
and the LTR sequence and reduced infection of CAR CD8 T cells by cell-free 
virus, as determined by culture supernatant p24 Gag (161).  They also reported 
less cell death in HIV-infected wells compared to mock wells when the shRNAs 
were incorporated.  Zhen et al. used a similar strategy, combining the CD4-zeta 
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CAR with a shRNA that targeted CCR5 and saw a reduction in intracellular Gag 
from cell-free virus (62).  Lastly, Hale et al. used homology directed insertion to 
deliver a PGT145 bNAb-based CAR to the CCR5 locus (162).  They saw more 
supernatant p24 accumulate when cell free virus was added onto PGT145 CAR 
CD8 T cells not treated with the CCR5-directed MegaTAL nuclease.  In line with 
these efforts, we utilized tools available to our lab which had previously or was 
concomitantly being tested to protect CD4 T cells from HIV infection.  We 
extended these technologies to determine the impacts of CCR5 ZFN coreceptor 
disruption as well as C34-CXCR4 peptide inhibition in CAR T cells.   
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Results  
 
Δ32 CD8 T cells delay HIV infection via the CD4 CAR compared to WT CD8 
T cells.  First, we wanted to determine to what extent the CCR5 coreceptor 
contributes to CD4 CAR-mediated infection.  To do this, we obtained CD8 T cells 
from either a normal, wild-type donor (WT) or a CCR5 Δ32 homozygote donor 
and transduced them to express the CD4 28z CAR.  We then set up a coculture 
with CD4 T cells from the WT donor that could propagate the CCR5-tropic Bal 
strain of HIV.  Compared to WT CD8 T cells transduced to express the CD4 28z 
CAR, the analogous Δ32 CD8 T cells had less intracellular Gag on days 4-6 (Fig 
3-1 A).  Curiously, after day 6 of infection, the amount of Gag skyrocketed in the 
Δ32 CD8 T cells, to levels greater than seen in the WT cells.  When looking at 
HIV spread throughout the WT CD4 T cell targets,  both WT and Δ32 effector 
CD8 T cells controlled HIV at the 1:25 and 1:50 E:T ratios, indicated by very low 
levels of Gag+ CD4 T cells (Fig 3-1 B).  The 1:100 E:T ratio looked similar to the 
pattern seen in CD8 T cells, with more control early on by the Δ32 effectors, 
which was then lost by day 8 (Fig 3-1 B).  As expected, by the 1:200 E:T ratio all 
control by the effectors had been diluted out.  No clear benefit in enrichment of 
the Δ32 CAR CD8 T cells was seen, relative to WT CAR CD8 T cells (Fig 3-1 C).  
This is not entirely surprising, given that the Δ32 CAR CD8 T cells succumbed to 
HIV infection at later timepoints, and there appeared to be a somewhat inverse 
correlation between the amount of intracellular Gag in the CD8 T cells (Fig 3-1 
A) and the frequency of CAR CD8 T cells (Fig 3-1 C).  Thus it appears that 
CCR5 does play a role in CAR-mediated infection, but the extent was difficult to 
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discern in our in vitro coculture.  The reason underlying this could have been due 
to either CCR5-independent membrane fusion, mediated by CAR CD8 T cells 
binding their target cells, or by CCR5 transfer via trogocytosis or microvesicles 
(163-165).    
 
Inefficient CCR5 ZFN disruption precludes detecting a benefit against HIV 
in vitro.  To determine if coreceptor editing promoted better enrichment of CAR 
CD8 T cells, we set up an in vitro coculture in which CD8 T cells were either left 
unmodified or treated with CCR5 ZFNs prior to CAR transduction.  Unfortunately 
no benefit to ZFN treatment was seen in this experiment (Fig 3-2 A-C), except 
for slightly increased enrichment of 28z and BBz CAR CD8 T cells treated with 
ZFNs, compared to their non-ZFN treated counterparts, at the 1:200 E:T ratio.  In 
fact, the ZFN-treated 28z and zeta CD8 T cells controlled HIV worse than their 
untreated counterparts at the 1:100 ratio (Fig 3-2 B and C).  It was 
retrospectively determined that the CCR5 disruption efficiency in the CD8 T cells 
had ranged from 5-7%, likely too small of a protected population to witness a 
benefit in a short, in vitro coculture.  This poor disruption efficiency was probably 
due to a batch of poor quality ZFN RNA, since members of the lab had previously 
demonstrated better editing capacity with CCR5 ZFNs, and we proceeded with in 
vivo studies using a fresh batch of ZFN RNA. 
 
CCR5-ZFN modified CD4 CAR CD8 T cells are enriched in a humanized 
mouse model of HIV infection.  After generating CD8 T cells with 
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approximately 45% of CCR5 alleles disrupted, we then included 4 additional 
cohorts of mice that were CCR5 ZFN treated to the HIV prevention humanized 
mouse model described in Fig 2-14.  For clarity, only the non-ZFN treated mice 
were shown in Chapter 2, though one large experiment was performed.  As 
mentioned previously, the groups were mice that received wild-type CD4 T cells 
and CD8 T cells that were either nontransduced (NTD), transduced with the 
optimized lentiviral vector containing either 4-1BB (BBz) or CD28 (28z) 
costimulatory domains, or transduced with the clinical trial MMLV-based vector 
(MMLV-CD4z).  Each of these groups had a ZFN-treated and non-ZFN treated 
counterpart, making a total of 8 CD8 T cell conditions.  After 3 weeks of HIV 
infection, CCR5 disrupted alleles were enriched in mice that were treated with 
CD4 CAR T cells, to varying degrees, relative to mock (uninfected) controls, with 
the most significant difference seen for the 28z CAR treated group (Fig 3-3 A).  
BBz had a high CCR5 disruption in the absence of HIV infection, likely due to the 
antigen-independent proliferation effects it imparts on T cells as shown in Fig 2-
17.  As expected, the CCR5 disruption was not increased in the presence of HIV 
for NTD CD8 T cells, which lacked the CD4 CAR and should not have been 
susceptible to HIV infection (Fig 3-3 A).  Surprisingly, CCR5 disruption appeared 
to be deleterious in the absence of HIV infection.  As mentioned, the CD8 T cells 
injected into the mice had approximately 45% of their CCR5 alleles disrupted, 
and were then diluted 1:5 with CD4 T cells.  While we tried to isolate pure 
populations of CD8 T cells, our splenocyte preparations were mostly CD4 T cells.  
Assuming the 1:5 dilution held true, we would expect on average about 9% 
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disruption efficiency in the absence of positive selection, but we saw less than 
1% CCR5 disruption in the absence of HIV in all cases except BBz.  
We also examined whether rendering CD4 CAR CD8 T cells resistant to 
HIV infection enhanced their ability to control HIV-1 infection.  In 28z or BBz 
mice, which had low viral loads in the absence of ZFN treatment, no further 
decrease in viral RNA resulted from ZFN treatment (Fig 3-3 B).  On the other 
hand, a significant decrease in plasma viral RNA was seen in mice given ZFN-
treated MMLV-CD4z T cells, to the point where plasma virus was no longer 
significantly higher than mice given the BBz or 28z CARs.  As the viral loads 
were approximately a log-fold higher in the MMLV-CD4z retrovirus treated mice 
without ZFNs compared to BBz or 28z treated mice without ZFNs, it is easier to 
detect a significant reduction in viral load in the context of poorly controlled virus 
replication resulting from ZFN treatment.  Moreover, the short duration of the 
experiment could have precluded seeing full benefit of ZFN treatment on CAR T 
cells, including a detectable enrichment of transduced CD8 T cells, particularly in 
the MMLV-CD4z treated mice in which they yielded the most antiviral benefit.  
ZFN treatment did not augment CD4 T cell expansion or increase CAR CD8 T 
cell counts, though there was a trend for increased values in the MMLV-CD4z 
treated mice (Fig 3-3 C-F).  There was also a trend for poorer counts in the 28z 
mice that received ZFNs, though these mice had lower CD4 T cell engraftments 
at baseline (Fig 3-3 C). 
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Lack of antiviral benefit of CCR5 ZFNs in an HIV treatment model.  After 
promising data with our HIV prevention model, we decided to include CCR5-
edited cells in our HIV treatment model, described in Fig 2-16, in which BBz or 
28z CD8 T cells were previously treated with CCR5 ZFNs.  This time we did not 
treat any NTD CD8 T cells with CCR5 ZFNs.  Prior to injection, the disruption 
frequency in the CD8 T cells was around 30%.  After approximately 3 weeks post 
ART removal, in the HIV-infected mice, we purified CD8 T cells from splenocytes 
and analyzed the CCR5 disruption and found that these values remained the 
same (Fig 3-4 A). We again saw a high disruption frequency in the mock BBz 
mice and a very low disruption frequency in the 28z mock mice, indicative of 
either or both an antigen-independent proliferation of the BBz CAR T cells and a 
negative selection in the absence of HIV infection against CCR5 disrupted alleles 
in the 28z mice (Fig 3-4A).  Similar to the results in Fig 3-3, CCR5 ZFN 
treatment afforded no benefit in terms of reducing HIV RNA in the mice treated 
with these optimized CARs (Fig 3-4 B).  However, in the HIV infected mice, ZFN 
treatment of CAR CD8 T cells increased both the CD4 and the CD8 T cell 
counts, relative to the non-ZFN treated cohorts, though this did not reach 
statistical significance (Fig 3-4 C and D, red dots).  By the experimental 
endpoint, both the CD4 and CD8 T cells were extremely high, likely due to xeno-
effects and GVHD.  This HIV antigen independent mechanism of proliferation 
may underlie the lack of enrichment seen in the CCR5 disrupted alleles in Fig 3-
4 A, and explain the difference between this data and Fig 3-3 A.   
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The C34-CXCR4 HIV fusion inhibitor augments control over HIV replication 
in vitro by the CD4 zeta CAR.  CCR5 surface staining is poorly resolved, so 
CCR5 disruption frequency must be determined by examining the proportion of 
cells with DNA disruptions.  Therefore, we cannot determine what proportion of 
cells are both HIV-resistant and CAR-transduced.  In contrast, the C34-CXCR4 
HIV fusion inhibitor is stably expressed on the cell surface an can be detected via 
surface staining, providing a method to determine which cells in culture are both 
HIV-resistance and CAR-transduced.  We therefore performed a dual 
transduction of CD8 T cells so that they would express a CD4 CAR as well as the 
C34-CXCR4 inhibitor.  C34-CXCR4 expression promoted better enrichment of 
CD4 CAR CD8 T cells at the 1:50 and 1:100 E:T ratios (Fig 3-5 A).  C34-CXCR4 
expression promoted better control over HIV replication at the 1:100 E:T ratio by 
the CD4 CAR T cells expressing the CD3-zeta (zeta) costimulatory domain, but 
did not augment control by CAR T cells expressing the BBz costimulatory 
domains (Fig 3-5 B and D).  A similar trend was seen in terms of infection of the 
CAR CD8 T cells, with addition of C34-CXCR4 preventing infection of the zeta 
CAR at the 1:100 E:T ratio (Fig 3-5 C).  The proportion of CD4 CAR+/C34-
CXCR4+ double positive cells slightly increased over time for the zeta construct, 
but decreased over time in the BBz wells that lost control over HIV infection, at 
the 1:50 and 1:100 E:T ratios (Fig 3-5 E).  These results indicate that C34-
CXCR4 can augment control over HIV replication and prevent infection of CAR T 
cells, but in this case a benefit was not seen for the BBz CAR.  We have 
previously shown that 4-1BB containing CD4 CARs function poorly in vitro 
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relative to CD4 CARs that contain only CD3-zeta (Fig 2-11), and they are more 
likely to succumb to HIV infection in vitro, and it is possible that that the C34-
CXCR4 fusion inhibitor may not be powerful enough to overcome this.  Whether 
or not this remains true in vivo is unknown. 
 
Bicistronic C34-2A-CAR vector reduces CD4 CAR MFI and result in poorer 
control over HIV.  Since the dual transduction inevitably results in mixed 
populations of cells, some of which are transduced with either vector alone, we 
reasoned that it might be beneficial to link CAR expression directly to expression 
of the fusion inhibitor.  Thus, we generated a bicistronic vector that linked the 
CD4 BBz CAR to the upstream C34-X4 fusion inhibitor with the T2A peptide 
cleavage sequence.  Compared to a single transduction with either C34-CXCR4 
or CD4 BBz alone, the 2A vector reduced the median fluorescent intensity (MFI) 
of C34 expression by about 75%  and CD4 CAR expression by about 60% (Fig 
3-6 A).  We then compared this 2A fusion construct directly to the dual 
transduction in a coculture experiment.  We found that the dual transduction 
controlled HIV spread throughout the CD4 T cells slightly better (Fig 3-6 B) and 
reduced HIV infection in the CAR+ T cells (Fig 3-6 C), particularly at the 1:50 and 
1:100 E:T ratios.  Interestingly, this benefit over control seemed to be due to the 
higher CD4 expression, rather than higher C34 expression, since the dual 
transduction (light blue) grouped closer to the unprotected control BBz alone 
(red), or a dual transduction with GFP (dark green), seen most clearly at the 
1:100 E:T ratio (Fig 3-6 C).  However, at the 1:100 and 1:200 E:T ratios, the 
103 
 
C34-2A-BBz CAR T cells enriched to a greater degree compared to the dual 
transduction (Fig 3-6 D).  Because you need infection and death of the non-
protected cells in order to see enrichment, it makes sense that we see better 
enrichment by the 2A vectors that allow for more HIV replication.  Together, 
these data indicate that linking the CD4 CAR expression to the fusion inhibitor is 
more detrimental than helpful, due to decreased surface expression of the CD4 
CAR.    
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Discussion 
 
 
We originally hypothesized that the CD4 CAR clinical trials failed to show 
durable reductions in HIV DNA, HIV RNA and infectious virus due to a lack of 
cytotoxicity.  However, as we performed our first in vitro studies in Chapter 2 we 
became aware that the CD4 CAR could be used as a surrogate receptor for HIV 
infection.  Indeed the original clinical trial construct succumbed to HIV infection at 
much lower E:T ratios than our re-engineered CD4 CAR constructs, which were 
expressed much higher levels on the cell surface and were superior at controlling 
HIV.  Nevertheless, it is possible that a combination of augmented cytotoxicity 
and protection from HIV infection will be required to achieve durable control by 
CAR T cells in HIV patients.  We therefore explored two methods to protect our 
CD4 CAR T cells, CCR5 disruption by ZFNs and stably expressing the C34-
CXCR4 fusion inhibitor, with the hypothesis that protected CAR T cells would 
control HIV better than unprotected CAR T cells in vitro and in vivo.   
Initially we tried to determine if HIV infection of CAR CD8 T cells was 
similar to natural cell infection in that it required a coreceptor, such as CCR5.  
Using a coculture of allogeneic WT CD4 T cells and CCR5 Δ32 CAR CD8 T cells, 
we found that despite an initial delay in HIV infection, the Δ32 cells resulted in 
robust HIV infection (Fig 3-1).  As mentioned, the CD4 CAR likely facilitated 
binding to HIV-infected target cells that expressed CCR5, and membrane fusion 
or vesicle transfer may have allowed the Δ32 cells to uptake both CCR5 and HIV 
(163-165).  It remains confusing why the peak Gag signal was higher in the Δ32 
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cells, though it may be explained by the fact that the WT CD8 T cells used in this 
experiment were autologous to the donor CD4 T cells.  Allogeneic effects or 
differences in effector cell health and function between the donors could have 
contributed to the higher levels of intracellular Gag in the CAR CD8 T cells and 
subsequent loss of control and spread in the CD4 T cells. 
We then looked at the benefits afforded by CCR5 disruption in CD4 CAR 
T cells in vivo in two humanized mouse models.  In the HIV prevention model, 
the proportion of CCR5 disrupted alleles increased in the HIV-infected mice given 
CD4 CAR CD8 T cells, relative to mock and relative to our predicted infusion 
disruption frequency around 9% (Fig 3-3).  This would indicate that those cells 
were infected by HIV in vivo and had a selective advantage in the presence of 
HIV, similar to what had previously been shown for CD4 T cells (83).  While we 
did not see an increase in the proportion of CCR5 disrupted alleles in the HIV 
treatment model, relative to the infusion product, this could be explained by the 
extensive proliferation from GVHD by the endpoint of the experiment.  By this 
timepoint, it is likely that the main cause of T cell proliferation was independent of 
HIV-antigen and CAR signaling.   
A surprising finding in this experiment was the strong negative selection in 
the absence of HIV within our mock control mice for all conditions except BBz.  In 
retrospect, this was also shown, albeit to a lesser extent, by Perez et al. They 
reported a lower frequency of CCR5 disrupted alleles in their mock NOG mice 
after a 40 day period, relative to the infusion product, whereas the HIV infected 
mice yielded an enriched proportion of CCR5-disrupted alleles (83).  Whether 
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this is a mouse-specific finding is unknown.  A recent clinical trial utilizing CCR5 
ZFNs only included HIV-infected patients, so the relative survival of modified 
cells in HIV-infected versus uninfected patients is not available (88).  In the 
future, it would be interesting to specifically label the CCR5 disrupted cells to 
analyze their trafficking and phenotypes, but as previously mentioned we cannot 
tell by simply staining for CCR5 at the cell surface.   
We then went on to utilize a second method of protection on our CAR T 
cells in which we could use surface staining to detect which cells were both CAR-
transduced and HIV resistant.  The benefits of the C34-CXCR4 fusion inhibitor 
were more readily detectable when using the CD3-zeta containing CAR, relative 
to the 4-1BB containing CAR in vitro.  Since the benefits of the 4-1BB 
costimulatory domain were clearly demonstrated in Fig 2-14 and 2-16, we asked 
whether coupling the CAR expression to the C34-CXCR4 expression would 
afford better protection and control over HIV in vitro.  A negative consequence of 
this was decreased surface expression of both the C34-CXCR4 and the CD4 
BBz CAR, and the bicistronic vector controlled HIV to a lesser extent than the 
dual transduction of two separate vectors expressing either C34-CXCR4 or the 
CD4 BBz CAR.  
The published reports of protecting CD4 CAR T cells CCR5 shRNA or 
surface-expressed GP41 based peptides were notably for cell-free virus 
infections, which never occurred in our hands with our optimized CARs.  This is 
likely because we optimized our CAR for cytolytic potential and showed in 
Chapter 2 that greater cytolytic potential reduces the E:T ratio at which CAR 
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CD8 T cells become infected.  The other, published reports typically used E:T 
ratios of 1:1 or higher, whereas our optimized CARs controlled at 1:50 or lower.  
Moreover, the reductions they reported were quite small in terms of the overall 
benefit, ranging in supernatant p24 or intracellular p24 reductions around 3% or 
less.  It is also interesting to consider the published mouse models by these 
groups.  Zhen et al. used the bone marrow-liver-thymus mouse model to 
generate CD4-zeta/CCR5 shRNA expressing hematopoietic stem cells; however 
they did not include a treatment group expressing solely the CD4-zeta CAR and 
without the CCR5 shRNA, analogous to our non-ZFN treated, CAR CD8 T cell 
injected mice (62).  Moreover, the follow-up Hale et al. study that included an 
NSG mouse model inserted a CD19-scFv CAR into the CCR5 locus with 
MegaTALs, and looked at tumor reduction rather than HIV-specific CAR function 
(166).  Thus, data demonstrating a clear in vivo benefit from protecting CAR T 
cells is lacking, despite initial reports of modest in vitro efficacy by these groups.   
Overall, we conclude that a high level of CD4 CAR expression is critical 
for controlling HIV replication and also preventing infection of the CAR T cells 
themselves.  While higher C34 expression logically seems like it would be critical 
for sufficient protection, our in vitro data emphasizes the importance of high CD4 
CAR expression over high C34 expression.  However, these short term co-
cultures may not represent the impact of protection in an in vivo infection in which 
CAR T cells may succumb to dysfunction and exhaustion if not protected.  Direct 
in vivo comparisons, not only of unprotected versus protected CAR T cells but 
also of the ZFN and the C34-CXCR4 protection methods, will be critical to 
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discern the best method for promoting long-term control.  Moreover it is possible 
that a combination of CCR5 disruption and co-expression of the CD4 CAR linked 
to the C34-CXCR4 fusion inhibitor may be the optimal solution.   
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Materials and methods 
 
Virus production and transduction. To generate lentiviral particles, expression 
vectors encoding VSV glycoprotein, HIV Gag and Pol, and Rev (pTRP pVSV-G, 
pTRP g/p.RRE  pTRP.REV) were synthesized by DNA 2.0 and transfected onto 
HEK293T cells with pTRPE transfer vectors using the Lipofectamine 2000 
transfection reagent (Invitrogen, Life Technologies) as previously described (96).  
Transfected HEK293T supernatant was collected at 24 and 48 hour timepoints, 
filtered through 0.45 um nylon syringe filters, and concentrated by 
ultracentrifugation at 18 hours at 8,500RPM at 4oC.  Medium was aspirated and 
pellet was resuspended in 1.2ml total volume and stored at -80oC.   
 
Cell culture. Purified CD4 and CD8 T lymphocytes were obtained by University 
of Pennsylvania Human Immunology Core/CFAR Immunology Core from de-
identified healthy donors.  T cells were purified by negative selection using the 
RosetteSep Human CD4+ or CD8+ T Cell Enrichment Cocktails according to the 
manufacturer’s protocols (StemCell Technologies). T cells were cultured at 1x106 
per mL in “complete RPMI 1640:”  RPMI 1640 (Life Technologies) supplemented 
(ThermoFisher Scientific) wih 10% fetal calf serum (Seradigm),  1% Penn Strep 
(Life Technologies), 2 mM GlutaMax (Life Technologies), and 25 mM HEPES 
buffer (Life Technologies).  T cells were stimulated with anti-CD3/CD28 coated 
Dynabeads (Life Technologies) at a 3:1 bead to cell ratio and 100-300 IU/mL of 
recombinant human interleukin-2 for 5 days prior to bead removal.  1 day after 
stimulation, 200ul of lentivirus supernatant was added to 0.5x106 cells.  MMLV 
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vector transduction was performed on days 3 and 5, with 1ml virus supernatant 
added to a Retronectin (Takara)-coated 24 well plate and spinoculated according 
to the manufacturer’s instructions.  Medium was doubled on day 3 and changed 
completely on day 5, and then added every other day throughout cell culture, or 
as necessary based on cell counts.   
 
CCR5 ZFN Disruption.  Previously described CCR5 specific ZFNs (88) were 
cloned into a RNA expression vector (167). The mMessage mMachine T7 
Transcription Kit (Ambion, Thermo Fisher Scientific) was utilized to generate 
capped, in vitro transcribed RNA, which was subsequently purified with the 
RNeasy Mini Kit (Qiagen) and eluted in RNase-free water at 1 mg/ml.  Normal 
donor CD8 T cells were washed three times with OPTI-MEM medium and re-
suspended at a final concentration of 1x108/ml prior to electroporation.  10E6 T 
cells in 0.1ml were mixed with 30μg of RNA encoding for each ZFN, 
electroporated in a 2 mm cuvette (Harvard Apparatus BTX) using an ECM830 
Electro Square Wave Porator (Harvard Apparatus BTX), and incubated at 30oC 
for 48 hours prior to activation with αCD3/αCD28 coated Dynabeads (Life 
Technologies).    
To measure efficiency of genome modification by CCR5 ZFNs, genomic 
DNA was purified from T cells and used to prepare samples for Illumina deep 
sequencing as described before (168). Briefly, the CCR5 target region was 
amplified and MiSeq adaptor was added using a nested PCR method with the 
following 2 CCR5-specific primer pairs. CCR5 Out-Out1 primers: 
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CTGTGCTTCAAGGTCCTTGTCTGC and CTCTGTCTCCTTCTACAGCCAAGC; 
CCR5 MiSeq adaptor primers: 
ACACGACGCTCTTCCGATCTNNNNNGCCAGGTTGAGCAGGTAGATG and 
GACGTGTGCTCTTCCGATCTGCTCTACTCACTGGTGTTCATCTTT. Sequence 
barcodes were then added in the subsequent PCR reaction using the barcode 
primer pairs. For analysis of gene modification levels, a custom-written computer 
script was used to merge paired-end 150bp sequences, and adapter trimmed via 
SeqPrep (John St. John, https://github.com/jstjohn/SeqPrep, unpublished). 
Reads were aligned to the wild-type template sequence. Merged reads were 
filtered using the following criteria: the 5’ and 3’ ends (23bp) must match the 
expected amplicon exactly, the read must not map to a different locus in the 
target genome as determined by Bowtie2 (169) with default settings, and  
deletions must be <70% of the amplicon size or <70bp long. Indel events in 
aligned sequences were defined as described previously (170), with the 
exceptions that indels of 1bp in length were also considered true indels to avoid 
undercounting real events, and true indels must include deletions occurring 
within the sequence spanning between the penultimate bases (adjacent to the 
gap) of the binding site for each partner ZFN.  
 
In vitro HIV replication control assay and intracellular Gag stain.  Two days 
after removing the anti-CD3/CD28 beads, CD4 T cells were infected with the 
CCR5-tropic HIV strain Bal, and 24 hours later were co-cultured at varying 
effector to target (E:T) ratios with CAR CD8 T cells.  Bal viral stocks (280ng/ml 
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p24) was prepared by harvesting the cell-free supernatant from anti CD3/CD28 
activated CD4 T cells and freezing in aliquots.  Activated CD4 T cells were 
infected by adding approximately 1ml of supernatant per 20 million cells 2-3 days 
after removing beads.  The following day CD4 and CD8 T cells were co-cultured 
at varying E:T ratios and HIV spread was monitored by intracellular p24 Gag with 
the KC57 anti-Gag-RD1 antibody (Beckman Coulter) and the Invitrogen Fix and 
Perm buffers, according the manufacturers’ instructions, gating on a population 
of uninfected cells.  To ensure that the same numbers of CAR CD8 T cells were 
being compared, we diluted out populations with higher transduction efficiencies 
by adding in nontransduced T cells until all CAR CD8 T cell populations matched 
the population with the lowest CAR or TCR transduction efficiency. 
 
Flow cytometry. CD4 CAR surface expression was monitored with mouse anti 
human CD8-FITC and anti-human CD4 APC antibodies (BD biosciences).  C34 
staining was performed using a monoclonal antibody, generated at 
GreenMountain Antibodies (Burlington, VT) as previously described (87). 
FluorescenceCells were visualized on a LSR II flow cytometer (BD Biosciences) 
and analyzed using Flowjo software (Tree Star).   
 
HIV prevention humanized mouse model. 6 week old NSG (NOD-
scid IL2Rgnull) mice were obtained from The Jackson Laboratory (JAX) and at 7 
weeks treated with 30mg/kg Busulfan mixed 1:1 with PBS.  24 hours later mice 
were injected via tail vein with 10x106 human lymphocytes in 100ul 0.5% human 
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serum albumin in PBS, comprised of 8 million CD4 T cells and 2 million CD8 T 
cells (NTD, BBz, 28z, or MMLV-CD4z transduced with a 50% transduction 
efficiency, either modified with CCR5 ZFNs or left unmodified)  Three weeks later 
mice were tail vein injected with 15ng HIV Bal mixed 1:1 with PBS. Peripheral 
blood was obtained by retro-orbital bleeding, and human CD4 T cell and CAR 
CD8 T cell counts were enumerated using BD lysis buffer and BD TruCount 
tubes as previously described (100), staining with  mouse anti human CD45 
PerCp Cy5.5 (BD Biosciences), mouse anti human CD4 BV421 (Biolegend), and 
mouse anti human CD8α BV711 (Biolegend). 
 
HIV treatment humanized mouse model. 5 week old NSG (NOD-scid IL2Rgnull) 
mice were obtained from The Jackson Laboratory (JAX) and at 6 weeks were 
injected with 5 million CD8-depleted human PBMCs, and 12 days later injected 
with 1 million HIV Bal-infected (or mock-infected) autologous CD4 T cells that 
had been in vitro infected with HIV Bal and cultured with ART for 2 days prior to 
freezing.  The same day as HIV infection, mice began receiving 200mg/kg daily 
intraperitoneal injections of the reverse transcriptase inhibitor nucleotide analog 
tenofovir disoproxil fumarate (TDF) for 4 days.  On Day 16, 5 million CD8 T cells 
were injected (NTD, BBz, or 28z) with a 50% transduction efficiency, either pre-
treated with CCR5 ZFNs or left ZFN untreated.  Peripheral blood was obtained 
by retro-orbital bleeding, and human CD4 T cell and CAR CD8 T cell counts were 
enumerated using BD lysis buffer and BD TruCount tubes as previously 
described (100), staining with  mouse anti human CD45 PerCp Cy5.5 (BD 
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Biosciences), mouse anti human CD4 BV421 (Biolegend), and mouse anti 
human CD8α BV711 (Biolegend). 
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Figures 
 
 
 
 
 
 
 
 
Figure 3-1.  Δ32 CD8 T cells delay HIV infection via the CD4 CAR compared to WT 
CD8 T cells.  CD4 T cells were obtained from a normal, CCR5 wild-type (WT) donor, 
infected with HIV Bal, and cocultured with autologous CD8 T cells or allogeneic CD8 T 
cells from a CCR5 Δ32 homozygote, both of which had been transduced to express the 
CD4 28z CAR.  (A) Shows the proportion of CD8 T cells that stained positively for 
intracellular HIV Gag. (B) Shows the proportion of CD8 negative T cells that stained 
positively for intracellular HIV Gag.  (C) Shows the proportions of CD4 CAR CD8 T cells 
over time in the cultures.  Samples were done in triplicate and the average values are 
plotted at each timepoint.   
 
 
 
 
116 
 
Figure 3-2. Inefficient CCR5 ZFN disruption precludes detecting a benefit against 
HIV in vitro.  Normal donor CD8 T cells were electroporated with CCR5 ZFN RNA and 
subsequently activated with αCD3/CD28 beads and transduced to express CD4 CARs 
with the BBz, 28z, or zeta costimulatory domains.  These CD8 T cells were then 
cocultured with autologous, HIV Bal-infected CD4 T cells and monitored for intracellular 
Gag and CAR expression over time.  (A) Shows the frequencies of CD4 CAR CD8 T 
cells over time in the cultures.  (B) Shows the proportion of CD8 negative T cells that 
stained positively for intracellular HIV Gag.  (C) Shows the proportion of gating on the 
CD8 T cells that stained positively for intracellular HIV Gag.  Samples were done in 
triplicate and the average values are plotted at each timepoint.   
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Figure 3-3.  CCR5-ZFN modified CD4 CAR CD8 T cells are enriched in a humanized 
mouse model of HIV infection.  Cohorts of NSG mice were infused with 8 million 
human CD4 T cells and 2 million human CD8 T cells (50% CAR transduction efficiency).  
CD8 T cells were either left mock electroporated or electroporated with CCR5 ZFN RNA, 
and subsequently left nontransduced (NTD) or transduced with optimized CD4 CARs 
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containing either 4-1BB or CD28 intracellular costimulatory domains, or the clinical trial, 
MMLV-based CAR, denoted in as NTD, BBz, 28z, and MMLV-CD4z, respectively.  
Three weeks post injection, mice were infected with HIV. (A) 22 days post infection mice 
were euthanized and CCR5 disruption PCR analysis was performed on CD8 T cells 
purified from splenocytes.  (B) 18 days post infection mice were bleed and HIV RNA 
copies per μl plasma were determined by qPCR and normalized to CD4 T cell counts.  
(C) Baseline CD4 T cell counts after 3 weeks of T cell engraftment (D) Endpoint CD4 T 
cell counts after 22 weeks of HIV infection (E) Baseline CAR CD8 T cell counts after 3 
weeks of T cell engraftment (F) Endpoint CAR CD8 T cell counts after 22 weeks of HIV 
infection.  Mann Whitney Test was used to determine statistical significance (p values: 
ns >0.05, *<0.05, **<0.01, ***<0.0001). 
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Figure 3-4.  Lack of antiviral benefit of CCR5 ZFNs in an HIV treatment model.  The 
experimental timeline and detailed description is provided in Fig 2-15. For logistical 
reasons the mice had to be terminated in two groups, with BBz mice terminated 21 days 
post ART removal and the NTD and 28z terminated 24 days post ART removal. (A)  
CCR5 disruption PCR analysis performed on CD8 T cells purified from splenocytes.  (B) 
At the endpoint termination bleeds HIV RNA copies per μl plasma were determined by 
qPCR and normalized to CD4 T cell counts.  (C) Endpoint termination CD4 T cell counts 
and (D) Endpoint termination CD8 T cell counts.  Mann Whitney Test was used to 
determine statistical significance (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001). 
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Figure 3-5.  The C34-CXCR4 HIV fusion inhibitor augments control over HIV 
replication in vitro by the CD4 zeta CAR.  Coculture results using normal donor, Bal-
infected CD4 T cells and autologous CD8 T cells transduced to express either a CD4 
CAR alone or dually transduced to express both a CD4 CAR and the C34-CXCR4 HIV 
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fusion inhibitor.  (A) Shows the proportions of CD4 CAR CD8 T cells over time in the 
cultures. (B) Shows the proportion of CD8 negative T cells that stained positively for 
intracellular HIV Gag at the 1:50 and 1:100 E:T ratios.  (C) Shows the proportion of CD8 
T cells that stained positively for intracellular HIV Gag.  Samples were done in singlet 
and these values are plotted at each timepoint.   
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Figure 3-6.  Bicistronic C34-2A-CAR vector reduces CD4 CAR MFI and result in 
poorer control over HIV.  Primary human CD4 and CD8 T cells were activated with 
αCD3/αCD28 coated beads and were transduced to express either monocistronic vector 
(C34-CXCR4 or CD4 BBz), the bicistronic vector C34-CXCR4-2A-CD4-BBz, or dually 
transduced with both the C34-CXCR4 and CD4 BBz vectors.  (A) After eight days T cells 
were stained for CAR and C34 surface expression by flow cytometry and the histograms 
of the CD8 T cells are depicted.   Median fluorescence intensity (MFI) for each condition 
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is indicated in the table to the right.  The CAR transduced CD4 and CD8 effector cells 
were then mixed 1:1 and added to a coculture with autologous HIV Bal infected CD4 T 
cells.  (B) Shows the proportion of CAR negative (CD4) T cells that stained positively for 
intracellular HIV Gag.  (C) Shows the proportion of CAR (CD4 high) T cells that stained 
positively for intracellular HIV Gag.  (D) Shows the proportion of CAR (CD4 high) T cells 
over time. Samples were done in duplicate and the average values are plotted at each 
timepoint.   
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CHAPTER 4 – Modeling CAR T cell killing of the latent reservoir 
 
 
Introduction   
 
While ART is capable of suppressing HIV replication in the blood, it cannot 
target the quiescent HIV reservoir, the source of virus reemergence after ART 
cessation (171).  Thus, the ultimate goal of HIV cure research is to maintain 
suppression of HIV in the absence of ART, whether by achieving effective 
immune control (a “functional cure”) or by purging the latent reservoir entirely 
(“sterilizing cure”) (172).  Methods of purging the latent reservoir have ranged 
from attempts to excise viral genomes using CRISPR to attempts to induce HIV 
expression using latency reversing agents (LRAs) to promote apoptosis by virus-
induced cytopathic effects (CPE) or cytotoxic immune recognition (49, 173, 174).  
However, virus rebound can occur even in patients with extremely small 
reservoirs, so it is unlikely that LRAs will induce sufficient CPE to remove all 
latently-infected cells.  Thus, it is conceivable that immune control mechanisms 
will be required for long-term suppression of HIV replication (175-177). 
 On one hand, a functional cure could be achieved by complete 
suppression of virus production, such as permanent silencing of proviruses. 
Attempts to silence proviruses have been made with ZFNs to incorporate KRAB 
DNA repression domains or to induce repressive chromatin marks (178-180).  On 
the other hand, a functional cure could be achieved by augmenting host-
mediated immune responses, and much effort has been spent trying to 
understand the determinants of immune control.  For example, elite controllers 
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suppress HIV to very low or undetectable levels in the absence of ART and never 
require therapy, whereas post-treatment controllers initiate ART early after 
infection and spontaneously control their virus after ART-removal at a frequency 
higher than predicted in the general HIV patient population (181, 182).  An active 
area of HIV cure research either attempts to enhance T cell responses to mimic 
elite controllers or attempts to augment additional immune control mechanisms.  
These immune-modulating strategies are widely diverse and include: therapeutic 
vaccination, adoptive cell transfer with dendritic cells or T cells, infusion of 
antibodies that neutralize HIV and/or recruit cellular effector mechanisms, 
infusion of antibodies to promote immune cell killing (such as PD-1 blocking 
antibodies, IFNα administration, among others (49, 183-187). 
Yet accurately modeling the in vivo efficacy of these developmental 
therapies in HIV patients is highly challenging.  An area of wide debate in the 
latency field is how best to model and how to measure the reservoir, either using 
in vitro models or animal models of latency (188, 189).  The pool of latently 
infected cell in patients is established early and maintained in resting cells over 
months or years by homeostatic and antigen-induced proliferation, accompanied 
by complex chromatin modifications in heterogeneous cell compartments located 
in different tissue compartments (190, 191).  This is difficult to recapitulate in 
short term cell culture models, which may use spinoculation to infect cells in vitro 
or result to artificial means to extend cell survival such as transduction with Bcl-2 
or addition of cytokines to promote infection of resting cells (188).  Other models 
have used ART patient cells, in attempts to model therapeutic treatment of 
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natural, patient reservoirs (192, 193).  Not only is this complicated by the rare 
frequency of latent cells in vivo, requiring collection of large numbers of PBMCs 
for analysis, but most proviruses are replication incompetent, so it is difficult to 
accurately estimate the true, infectious HIV reservoir (191, 194).   
Many classes of LRAs have been developed, though none have been 
explored as extensively as histone deacetylace inhibitors (HDACi), many of 
which have been employed in clinical trials after successful in vitro data (195).   
We tested three of these agents which had made it to clinical testing phases due 
to their HIV-activation effects and lack of overt toxicity: SAHA (Vorinostat), 
Romidepsin, and Panobinostat.  However, both in our hands an others, HDACi’s 
have failed to live up to their initial promise (to be discussed below).  One 
challenge that has been met with the LRA approach, regardless of the class of 
drug used, is that cells are not uniformly activated (even with ex vivo drug 
treatment) to produce virus, and multiple stimulations can induce sequential 
bursts of virus production, so it is difficult to gauge the true proportion of cells 
harboring replication-competent, inducible proviruses (194).   
The ultimate goal of this dissertation is to create CAR T cells that are 
capable of suppressing HIV in patients after ART removal, enabling a functional 
cure.  This could be achieved by long-term cell CAR T survival combined with 
rapid killing kinetics that could eliminate latently-infected cells prior to virion 
release, which has been shown for T cells from HIV viremic controllers (196).  
The data presented in Chapters 2 and 3 focused on enhancing CAR T cell 
cytotoxicity and function, using models that employed activated, normal human 
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donor T cells, infected with a lab grown strain of HIV.  This allowed us to achieve 
maximal production of virus and a high proportion of Gag+, HIV-infected CD4 T 
cells, which allowed us to easily detect differences in HIV control and HIV spread 
between  wells with different CAR conditions being compared.  However, the 
infected target cells in HIV patients will likely be a relatively rare population of 
resting cells, producing much fewer virions than those utilized in our in vitro 
activated cell assays.  Moreover, virus evolution over months or years in a 
patient may result in a quasispecies unlike our Bal infections (197).  Therefore, 
we attempted to model the latent reservoir in order to determine if CAR CD8 T 
cells, including those from HIV donors, could kill resting CD4 T cells from patients 
on ART.  We furthermore included various HDACi LRAs in these models to 
determine if they enhanced HIV expression and CAR CD8 T cell killing. 
. 
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Results: 
 
CD4 CAR CD8 T cells reduce HIV Gag in a spinoculation model of HIV 
latency.  To determine if CAR CD8 T cells are capable of targeting resting CD4 
T cells producing low levels of HIV, we collaborated with the laboratory of Dr. 
Una O’Doherty, which had previously established a spinoculation model of HIV 
latency (198).  In this model, HIV supernatants are centrifuged along with resting 
normal donor CD4 T cells, and following this spinoculation process the CD4 T 
cells are washed and then cultured alone or cocultured with CD8 T cells that 
were either left nontransfected (NTD) or transfected with CD4 CAR RNA.  In 
addition, LRAs can be added such as the HDACi SAHA, which was included in 
the model shown in Fig 4-1.  After a 48 hour coculture, the wells were collected 
and stained for intracellular Gag and measured by flow cytometry.  HIV infected 
cells cultured alone were approximately 4% Gag+ (Fig 4-1B), whereas those 
cultured in the presence of SAHA actually had less Gag (2.5%, Fig 4-1C).  
Culturing in non-transfected (NTD) control CD8 T cells increased Gag relative to 
the CD4s with SAHA (Fig 4-1D).  In contrast, culturing CD4 CAR transfected 
CD8 T cells, either in vehicle control or in the presence of SAHA reduced HIV 
down to approximately 1-1.5% (Fig 4-1E and F).  Of note, a mutant version of 
CD4 (which was comprised of domain 1 of CD4 and mutated to bind Env with 
higher affinity) was utilized as the HIV-binding domain of the CAR in this 
experiment (199).  These preliminary results suggested CD4 CAR T cells could 
target resting cells expressing lower levels of HIV than our activated CD4 T cell 
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system shown in Chapters 2 and 3.  While this model augmented the proportion 
of “latent” HIV-infected cells and allowed us to detect CAR T cell killing, we 
wanted to better represent treatment of patients’ viral reservoirs, and so future 
experiments utilized CD4 T cells from patients on ART 
 
Intracellular Gag staining is not sensitive enough to detect CAR T cell 
reduction of HIV in ART patient CD4 T cells.  We next performed coculture 
experiments with CAR-transduced CD8 T cells mixed in with CD4 T cells from 
patients on ART, in the presence LRAs to augment virus production.  As the 
proportion of latently infected cells in ART patients is typically 1 in 104 or 105 
cells, we reasoned that we would need to augment the production of HIV in order 
to detect a reduction in the proportion of HIV-infected cells treated with CAR CD8 
T cells (200).  We therefore, used a variety of LRAs including the HDACis SAHA 
and Romidepsin, a protein kinase C agonist termed C7A, and the BET protein 
inhibitor JQ1 and collected large numbers of CD4 T cells.  As expected, the 
baseline proportion of intracellular Gag+ cells identified by flow cytometry was 
extremely low, at less than 0.1% (Fig 4-2A).  Unfortunately, we were unable to 
see consistent increases in the proportion of Gag+ cells upon treatment with the 
various LRAs (Fig 4-2A, and data not shown).  Moreover, treatment with 
αCD3/αCD28 coated beads only increased the proportion of Gag+ cells by a 
small fraction (i.e. 0.1% of cells to 0.5%, Fig 4-2A), despite evidence of cellular 
activation upon αCD3/αCD28 stimulation, as evidenced by an upregulation of 
CD69 surface expression (Fig 4-2B).  In contrast to our predictions, coculturing 
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CD8 T cells, regardless of CAR expression, slightly increased activation of the 
CD4 T cells and the proportion of Gag+ cells (Fig 4-2).  Based on these 
experiments, we concluded that we would need to collect an unfeasible number 
of cells per condition to get a reliable proportion of Gag+ cells, and decided to 
utilize other methods to measure the HIV reservoir besides intracellular Gag 
staining and flow cytometry. 
 
Integrated HIV DNA is more readily detected in ART patient cells.  We 
returned to our collaboration with the O’Doherty lab to utilize their established 
assay to measure integrated HIV DNA in cells from ART patients (201, 202).  We 
set up a 24 hour coculture similar to that described in Fig 4-2, culturing ART 
patient CD4 T cells alone, or in the presence of unmodified control CD8 T cells 
(NTD), lentivirally transduced CD4 CAR CD8 T cells (preactivated), or RNA-
transfected, resting CD4 CAR CD8 T cells.  We utilized Romidepsin as the LRA 
in this experiment and also looked at the effects in the presence of ART, which 
would prevent viral spread in the event of latent cell reactivation.  After a 24 hour 
coculture, the wells were analyzed for the proportion of HIV DNA per million cells.  
There was a reduction of integrated HIV DNA in conditions given LRAs with 
either CAR CD8 T cell condition, relative to NTD control CD8 T cells or CD4 T 
cells cultured alone (Fig 4-3, green and turquoise bars).  However, why these 
values would be higher for the NTD coculture wells relative to CD4 only T cells 
remains perplexing, though we did not measure cellular activation in these 
experiments, and it is possible the CD8 T cell coculture wells were more 
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activated and stimulatory to HIV in general; though in that case we could expect 
all NTD CD8 wells to have higher HIV DNA levels, including –LRA+ART 
condition (Fig 4-3, purple bars).  Around the same time, new technology was 
being developed to measure ultrasensitive p24 values.  We validated this 
technology in our HIV-treatment mouse model shown in Fig 2-16 and decided to 
employ this assay to measure HIV in reservoir cells in the hopes that this high 
throughput assay could provide more robust data. 
 
Ultrasensitive p24 detection can be used to measure CAR T cell killing of 
ART patient cells.  The SIMOA HD-1 analyzer is a high throughput assay that 
uses ultrasensitive ELISA technology to detect HIV p24 Gag protein.  Measuring 
p24 Gag protein production may better estimate the size of the infectious 
reservoir compared to a PCR that amplifies only a small portion of the HIV 
genome, such as the integrated DNA assay we were using (194).  To our 
surprise, we found out that this assay is sensitive enough to detect leftover p24 
from the lentivirus packaging plasmids (data not shown).  Therefore, we 
employed RNA transfected CD8 T cells in coculture assays to avoid false 
positive HIV detection of the lentiviral vector.  Moving forward, we chose to 
employ the LRA panobinostat in place of romidepsin, since it was effective in 
published latency models and was less toxic to activated lymphocytes in our 
hands as well as others (203, 204).  We also compared the effects on p24 
protein levels by resting CD8 T cells versus those that had been previously 
activated with αCD3/αCD28 coated beads, prior to electroporation of CD4 CAR 
132 
 
RNA.  After a 72 hour coculture of normal donor CD8 T cells cultured with ART 
patient CD4 T cells, panobinostat generally increased p24 protein in control wells 
cultured with NTD CD8 T cells, relative to DMSO treatment (Fig 4-4, black 
bars).  In addition, there was a trend toward lower levels of p24 in wells with 
either the pre-activated or resting CAR CD8 T cells, relative to the NTD CD8 T 
cell wells (Fig 4-4).  As the resting CD8 T cell wells were as good, if not better, 
than previously activated CD8 T cells, we chose to use resting cells in a similar 
assay in which only the 20nM panobinostat treatment was examined.  To 
determine if ART patient CD8 T cells yielded similar results to normal donor CD8 
T cells, which had been used in almost all of our previous assays, we purified 
autologous, ART patient CD8 T cells from the same donor as the CD4 T cells 
and compared their ability to reduce p24 to normal donor, allogeneic CD8 T cells.  
In contrast with the previous experiment, panobinostat did not consistently 
increase p24 compared to DMSO controls in the NTD CD8 T cell cocultures (Fig 
4-5, black bars).  Surprisingly, in the presence of panobinostat we saw a robust 
augmentation of p24 production in CAR CD8 T cell coculture wells relative to 
NTD CD8 T cell control wells (Fig 4-5).  Since panobinostat inconsistently 
activated HIV p24 protein production and has also been shown to impair CD8 T 
cell proliferation and activation, albeit less than romidepsin, we discontinued this 
LRA strategy (205, 206).  At the same time, promising results with the IL-15 
superagonist ALT-803 demonstrated HIV-activating potential with fewer 
detrimental impacts on CTL responses (205).  A pilot experiment was set up 
comparing the HIV-activating effects of the IL-15 superagonist (IL15 SA), 20IU/ml 
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IL-2, 5ng/ul IL-7, or combinations of these drugs.  Higher background levels of 
p24 were observed in this experiment, but addition of the IL15 SA increased p24 
in the NTD CD8 T cell control wells, compared to DMSO, IL2 or IL7 treatment 
(Fig 4-5).  Moreover, in all conditions except the IL2 treatment wells, CAR RNA 
electroporated CD8 T cells reduced p24 relative to NTD controls (Fig 4-5).  While 
it is widely known that IL2 robustly activates T cells, others have reported 
minimal or low HIV p24 production when IL2 was used as an LRA, somewhat 
replicated by our data (205, 207).  Together these assays demonstrate potential 
for the SIMOA technology to determine the efficacy of CD4 CAR T cells towards 
ART patient cells, but also demonstrate the need for LRAs capable of reliably 
promoting HIV expression. 
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Discussion 
 
Overall, these data highlight the complexity of modeling and measuring 
the latent HIV reservoir.  We are not alone in this challenge, and the latency field 
has experienced much difficulty and debate over which models, measurements, 
and stimulatory LRAs to use (208-210).  After a proof of principle analysis of CAR 
CD8 T cell killing an in vitro spinoculation model with resting CD4 T cells (Fig 4-
1), we chose to study the “natural” reservoir in ART patient cells.  However, a 
major downside to this is the low frequency of HIV+ CD4 T cells, making it difficult 
to detect infected cells and even more difficult to detect reliable reductions in HIV 
reservoirs achieved through the use of CAR T cells, whether measured by 
intracellular Gag staining (Fig 4-2), HIV DNA (Fig 4-3), or p24 protein (Figs 4-3, 
4-4, and 4-5).   
Further complicating this is the inability of LRAs to uniformly promote HIV 
activation without T cell activation and/or toxicity.  Initially, promising data was 
achieved with the HDACi’s we chose to employ, SAHA, Romidepsin, and 
Panobinostat (177, 211, 212).  However, toxicity and lack of efficacy in in vitro 
assays, both in our hands and in others has diminished the outlook of those 
LRAs, at least as single agents (213, 214).  Despite initial promising results with 
vorinostat in activating HIV mRNA in patients, its effects waned with additional 
dosing and no reservoir reduction was seen (215). Romidepsin and Panobinostat 
similarly did not reduce patients’ reservoirs despite increasing plasma HIV RNA 
(210, 216).   
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The lack of a consistent and detectable p24 signal in the absence of LRAs 
demonstrates the need for better LRAs; in order to develop better models to 
measure reductions in the reservoir, such as those achievable by CAR T cells, 
we need to have a positive value to begin with.  The caveat is that the positive 
controls that have been used to induce maximum virus production, such as 
αCD3/CD28 or PMA/Ionomycin, activate T cells so that they no longer represent 
the quiescent, latent state that will have to be targeted in vivo.  
Additional challenges to achieving robust datasets include intra-patient 
and inter-patient heterogeneity in the ability of LRAs to activate all T cells from an 
individual or similarly activate cells between different individuals (193, 217).  
Once virus is reactivated, it is unknown what measurement is best as the 
numerous assays employed to quantify the HIV reservoir show little correlation; 
although the huge proportion of proviruses with internal deletions and lethal 
mutations can account for some of this (192, 194, 210).   
While we have some promising preliminary data utilizing an ultrasensitive 
p24 ELISA, the data are a work in progress that require optimization prior to 
generating publication quality results.  More donors and replicates will be 
required in order to gauge the variability within patients and between samples.  
Nevertheless hope remains that the right combinations or new drugs could prove 
efficacious (218).  Recently, Descours et al. described CD32a as a biomarker for 
the latent reservoir (219).  This is exciting, as reservoir biomarkers could facilitate 
cell sorting to enrich for HIV+ cells, and this could allow for better models of the 
reservoir in which to detect reduction and killing of latently infected cells. 
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Materials and methods 
 
Plasmid construction.  The CD4 zeta sequence was cloned  into the pGEM and 
pDA RNA expression plasmids containing the T7 promoter using the XbaI and 
SalI restriction sites.  pGEM was linearized with Sal1 and pDA was linearized 
with SpeI prior to in vitro transcription. 
 
In vitro transcription.  RNA was created as previously described (220) using 
the mMESSAGE mMACHINE T7 ULTRA transcription kit (Thermo Fisher 
Scientific), according to the manufacturer’s protocols.  RNA was purified using 
the RNeasy Mini Kit (Qiagen).  
 
Cell Culture. Purified CD4 and CD8 T lymphocytes were obtained by University 
of Pennsylvania Human Immunology Core/CFAR Immunology Core from de-
identified healthy donors or ART patients.  Normal donor T cells were purified by 
negative selection, unless otherwise stated below, using the RosetteSep Human 
CD4+ or CD8+ T Cell Enrichment Cocktails according to the manufacturer’s 
protocols (StemCell Technologies).  For figures 4-3 and 4-4, the HIV donor CD4 
T cells were purified by human CD4 microbeads (Miltenyi Biotec).  For figure 4-5 
and 4-6, HIV donor CD4 T cells were purified using the EasySep Human CD4+ T 
Cell Isolation Kit (StemCell Technologies).  For figure 4-5 the HIV donor CD8 T 
cells were purified using the EasySep Human CD8 Positive Selection Kit II 
(StemCell Technologies).  T cells were cultured at 1x106 per mL in “complete 
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RPMI 1640:”  RPMI 1640 (Life Technologies) supplemented (ThermoFisher 
Scientific) wih 10% fetal calf serum (Seradigm),  1% Penn Strep (Life 
Technologies), 2 mM GlutaMax (Life Technologies), and 25 mM HEPES buffer 
(Life Technologies).   
 
CAR RNA electroporation into CD8 T cells.  CD8 T cells were either left 
resting or activated using αCD3/αCD28 coated Dynabeads (Life Technologies) at 
a 3:1 bead to cell ratio and 100 IU/mL of recombinant human IL-2.  Beads were 
removed on day 5 and cells were electroporated on day 8.  For electroporation, 
cells were washed three times with OPTI-MEM medium (Invitrogen) and 
resuspended in OPTI-MEM at 1x108 cells/ml.  Subsequently, 0.1ml, or 1x107 
cells, were mixed with 10μg of RNA and transferred to a 0.2 cm Gene Pulser 
cuvette (BioRad) and electroporated using the BTX ECM830 Electro Square 
Porator (Harvard Apparatus).  The settubgs were 500V for 700μs for resting cells 
or 360V for 1ms for activated cells.  Cells incubated for at least 4-24 hours and 
then cocultured in with the CD4 T cells. 
 
In vitro spinoculation HIV latency assay.  Spinoculation assay was performed 
as previously described (198) on normal donor, human CD4 T cells.  Cells were 
centrifuged 1500RPM, and resuspended in 100ul per 1x106 cells of NL4-3 virus 
supernatant, which was prepared in 293T cells by the University of 
Pennsylvania’s Center for AIDS Research Viral/Molecular Core, and added to 
wells of a 96 well plate.  This was then centrifuged at 1,200 x g for 2 hours at RT.  
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After spinoculation, cells were washed twice in CO2 independent media 
(Invitrogen) and treated with 50 mg/mL Dnase I (Roche) and 10 mM MgCl2 to 
remove plasmid DNA. Cells were then cultured at 4x106/ml in 300ul a 96 well 
plate the presence of 1.25 mM of the protease inhibitor saquinavir (Roche) to 
prevent viral spread.  Cells were cultured alone or 1:1 with control or RNA-
transfected CD8 T cells for 48 hours prior to staining for intracellular Gag.  In the 
denoted wells 1uM SAHA was added, or DMSO control.  
 
In vitro coculture with ART patient cells.   CD4 and CD8 T cells were 
cocultured in 1ml of culture medium in a 48 well plate (or a 24 well plate for 
Figure 2) for 16-72 hours and then wells were collected for intracellular Gag 
staining, integrated HIV DNA qPCR, or HIV p24 protein analysis.  E:Ts ranging 
from 1:4 to 1:10 were used, depending on the number of cells available, with 1-4 
million CD4 T cells cultured with 0.1-0.4 million CD8 T cells.   
 
Integration analysis.  RNA-free DNA was isolated with the Gentra Puregene 
Cell Kit (Qiagen, #158745) according to the manufacturer’s guidelines.  Total 
genomic DNA (gDNA) was quantified through qPCR of the albumin gene.  
Integrated HIV was quantified in an Alu-HIV, two-step PCR protocol (202, 221), 
with the following modifications.  gDNA was diluted down until 20-80% of PCR 
reactions containing the given amount of gDNA were positive for HIV DNA.  HIV-
positive wells are quantified through a presence-absence qPCR assay.  These 
measurements follow the Poisson distribution, which can be used to calculate the 
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number of HIV copies per given amount of gDNA independent of a standard 
curve (222).  To control for linear amplification from unintegrated HIV, 8-wells 
containing only the HIV-specific primer were included for each measured sample, 
and HIV-positives wells with a cycle-threshold (Ct) falling within 2 standard 
deviations of the average Ct from Linear-HIV wells were excluded.  Using this 
method, we can calculate 2-fold changes in integrated HIV-DNA. 
 
Ultrasensitive p24 detection.  Cells pellets were lysed in 1% triton x-100 in PBS 
and diluted according to a protocol supplied by Bonnie Howell (Merck & Co, Inc.).  
The HIV p24 Gag protein was measured using the p24 single molecule array 
using the Simoa HD-1 Analyzer (Quanterix) following the manufacturer’s 
instructions.  Each sample was measured in duplicate and concentration 
calculated based on a standard curve. The average concentration of two 
replicates for each sample was reported.  The accurate detection range was 
0.008pg/ml to 39.5pg/ml. 
 
Flow cytometry.  CD4 CAR surface expression was monitored with mouse anti 
human CD8-FITC and anti-human CD4 APC antibodies (BD biosciences).  Cells 
were visualized on a LSR II flow cytometer (BD Biosciences) and analyzed 
using Flowjo software (Tree Star).  HIV was detected intracellular p24 Gag with 
the KC57 anti-Gag-RD1 antibody (Beckman Coulter) and the Invitrogen Fix and 
Perm buffers, according the manufacturers’ instructions. 
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Figures: 
 
 
 
 
 
Figure 4-1. CD4 CAR CD8 T cells reduce HIV Gag in a spinoculation model of HIV 
latency.  Intracellular Gag staining performed after a 48 hour coculture on resting 
spinoculated CD4 T cells either (A) left uninfected (B) HIV-infected (C) cultured with 1uM 
SAHA (D) cultured 1:1 with autologous nontransfected (NTD) CD8 T cells and 1uM 
SAHA (E) cultured 1:1 with CD4 CAR RNA transfected CD8 T cells and 1uM SAHA  or 
(F) cultured 1:1 with CD4 CAR RNA  transfected CD8 T cells. 
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Figure 4-2. Intracellular Gag staining is not sensitive enough to detect CAR T cell 
reduction of HIV in ART patient CD4 T cells.  CD4 T cells were isolated from ART 
patient PBMCs and cultured for 16 hours alone or in the presence of nontransduced or 
CD4 CAR transduced allogeneic, normal donor CD8 T cells at a 1:10 E:T ratio.  
Additionally, 0.1mM C7A or DMSO control was added or a 3:1 ratio of αCD3/αCD28 
coated beads.  After 16 hours, the wells were collected and stained for (A) intracellular 
Gag and (B) CD69 expression. 
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Figure 4-3. Integrated HIV DNA is more readily detected in ART patient cells. CD4 
T cells were isolated from ART patient PBMCs and cultured alone or in the presence of 
allogeneic, normal donor unmodified control CD8 T cells (NTD), lentivirally transduced 
CAR CD8 T cells (preactivated), or RNA-transfected, resting CAR CD8 T cells at a 1:4 
E:T ratio.  In addition, either 40uM romidepsin or ART (efavirenz, saquinavir, and 
raltegravir, 1uM each) was added to designated wells.  After 24hours, wells were 
collected and cells were lysed for analysis of integrated HIV DNA by qPCR, reporting the 
integrated HIV DNA copies per million cells.        
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Figure 4-4. Panobinostat increases HIV p24 Gag compared to DMSO.  CD4 T cells 
were isolated from ART patient PBMCs and cultured or in the presence of 
nontransfected (NTD) or CD4 CAR transfected allogeneic, normal donor CD8 T cells at 
a 1:10 E:T ratio that were either left resting or preactivated with αCD3/αCD28 coated 
bead.   Either vehicle control (DMSO) or the indicated concentrations of panobinostat 
were added to the wells at the time of coculture.  After 72 hours the wells were collected 
and cell lysate analyzed for p24 Gag. 
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Figure 4-5. Panobinostat activates robust HIV p24 Gag production in the presence 
of CAR CD8 T cell.  CD4 T cells were isolated from ART patient PBMCs and cultured or 
in the presence of nontransfected (NTD) or CD4 CAR transfected CD8 T cells at a 1:10 
E:T ratio.  CD8 T cells were either isolated from an allogeneic, normal donor (ND 8s) or 
from the autologous CD4 T cell donor (HIV 8s).  Either vehicle control (DMSO) or the 
20nM panobinostat was added to the wells at the time of coculture.   After 24 or 72 
hours, the wells were collected and cell lysate analyzed for p24 Gag. 
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Figure 4-6. IL15 SA activates HIV relative to DMSO and allows for detection of CAR 
CD8 T cell killing.  CD4 T cells were isolated from ART patient PBMCs and cultured or 
in the presence of nontransfected (NTD) or CD4 CAR transfected  allogeneic, normal 
donor CD8 T cells at a 1:5 E:T ratio.  Either vehicle control (DMSO) or 1.7nM IL-15 
superagonist (IL15 SA), 20IU/ml IL-2, 5ng/ul IL-7 was added to the wells at the time of 
coculture.   After 24 hours, the wells were collected and cell lysate analyzed for p24 
Gag. 
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CHAPTER 5 – Conclusions and Future Directions 
 
 
Given the relatively recent discovery of HIV-1 and the extremely complex 
biology of the virus, it is awe-inspiring to consider how rapidly the ACT efforts for 
HIV progressed.  Less than a decade after the initial reports that CD8 T cells 
both contribute to control over HIV and shape virus escape, efforts were 
underway to augment host CTL responses using ACT (49).  Unfortunately, HIV 
escape from autologous, expanded HIV-specific CTLs and a lack of efficacy of 
the transferred cells, combined with the concomitant development of highly 
effective ART regimens, largely halted the pursuit of these strategies for HIV 
treatment.  Among these trials were the initial CD4-zeta CAR T cell infusions, 
which were found to be safe but did not reduce the HIV reservoir consistently or 
durably enough to warrant infusion into larger cohorts of patients (42, 43). 
Nevertheless, T cell based ACT approaches are still being explored by a 
handful of HIV laboratories around the world in the hopes that augmented control 
will be achieved with new technologies.  Diverse T-cell expressed antiviral 
transgenes, including antisense RNA and dominant negative HIV Tat and Rev 
proteins, have made their way to the clinic, but have largely been unsuccessful 
(49).  On the other hand, the recent, promising clinical trial results using CCR5 
ZFN-edited autologous CD4 T cells have renewed interest in the role that gene-
edited T cells may play in a functional HIV cure (88).  At the same time another 
clinical trial is underway using an alternative method to protect CD4 T cells, with 
a GP41-based C34 peptide fused to the N terminus of the CXCR4 HIV 
coreceptor (NCT03020524).  These strategies hold the possibility of protecting 
147 
 
critical populations of natural patient effector and helper T cells to augment their 
functionality and mimic elite controller phenotypes with long-term suppression in 
the absence of ART.   
We hypothesized that the most promising avenue for T cell based ACT 
would be through re-engineering CARs with increased survival and effector 
potential to target HIV.  Taking advantage of many scientific advances made in 
the ACT field during the 15 years following the initial CD4-zeta CAR clinical trials, 
we undertook a project to re-design this CAR in an effort to augment control over 
HIV, with the ultimate goal of generating a clinically viable therapy.  Throughout 
this project we learned many lessons and identified many avenues that remain 
underexplored regarding these CD4 CARs, which will be discussed below.  
 
Major lessons learned 
 
Augmenting CAR expression greatly enhances control over HIV replication.  
As discussed in Chapter 2, CAR expression was greatly improved by a 
combination of substituting a lentiviral expression vector for the MMLV-based 
vector and the EF1α promoter for the PGK promoter.  The enhanced control over 
HIV replication in culture achieved by these two, simple modifications was 
surprising, with CAR CD8 T cells that could now control HIV down to a 1:50 E:T 
ratio when the original vector lost control past a 1:1 ratio.  However, other factors 
clearly play important roles as well.  For instance, swapping the CD8α 
transmembrane (TM) for the CD4 TM domain augmented control while slightly 
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reducing CAR surface expression.  While we demonstrated less infection in the 
CAR T cells containing the CD8α TM domain, it is possible that this benefit can 
also be attributed to dimerization and signaling differences that enhance CAR T 
cell functionality. 
 
The 4-1BB costimulatory domain promotes effective in vivo control over 
HIV in humanized mice, despite poorer control in vitro.  Based on our in vitro 
studies, we were fairly certain that a CAR containing CD28 (28z) was the most 
promising clinical candidate due to its potent in vitro control and cytokine 
production, relative to 4-1BB containing CARs (BBz).  Nevertheless, clinical 
evidence as well as mouse tumor models supported the use of 4-1BB in tumor-
specific CAR T cells, so we decided to include it in our humanized mouse models 
of HIV infection (16, 31, 54).  To our surprise, 4-1BB containing CD4 CARs 
provided superior control over HIV in two different scenarios: early on in an HIV 
prevention model in which CAR CD8 T cells were injected prior to HIV, and also 
durable control in an HIV treatment model.  Early on in the HIV prevention model, 
higher BBz CAR T cell counts and lower plasma HIV RNA were observed, 
relative to 28z CAR T cells.  With time (and antigen exposure), 28z T cells caught 
up and similar viral loads were observed by the experimental endpoint.  In our 
HIV treatment model, we had similar numbers of BBz and 28z CD8 T cells early 
on and again saw similar levels of control when the BBz and 28z CAR T cell 
numbers matched.  However, as BBz out-proliferated the 28z CD8 T cells, we 
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saw maintenance of control by BBz only, whereas 28z then lost control to the 
extent that the viral loads matched NTD mice.   
We further observed an antigen-independent survival and proliferation of 
the BBz CAR T cells, but not the 28z cells, in uninfected mice.  This was not 
entirely surprising, as antigen independent cell survival was reported in vitro for 
the CD19-BBz CAR (16).  There is a lack of published literature describing the 
effects of BBz CAR T cells in an antigen independent setting, such as in tumor 
free mice, though it is highly unlikely these experiments have not been 
performed.  For example, as part of a study utilizing SS1 mesothelin-directed 
CARs members of the June lab compared survival of SS1 CAR T cells containing 
4-1BB, CD28, and ICOS in both tumor-injected and tumor-free mice, but only 
published data on tumor free mice injected with ICOS CAR T cells (223).  
However, they saw a pattern similar to us, with enhanced survival of SS1-BBz 
CAR T cells in the tumor free mice, relative to both the 28z and ICOSz mice 
(data unpublished).   
The ability of CAR T cells to survive long-term, or at least temporarily, in 
the absence of antigen is a critical therapeutic consideration, as patients will 
likely be on ART when CAR T cells would be infused.  This survival benefit may 
outweigh the effector phenotype advantage that CD28 theoretically imparts.  
Zhao et al. found that CD28 intracellular costimulatory domains promote greater 
functional potential in CAR T cells, but 4-1BB is critical for survival (57).  
Interestingly, both persistence and anti-tumor functionality could be increased in 
the 28z CAR T cells by including the 4-1BBL as part of a bicistonic vector, but not 
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by a third generation CAR expressing both CD28 and 4-1BB intracellular 
costimulatory domain.  It would be worthwhile to determine if this combination 
could similarly augment control over HIV in vivo with our CD28 containing CD4 
CAR T cells.   
 
CAR expression renders T cells susceptible to HIV infection. While a handful 
of papers have recently been published that describe the capacity of the CD4 
CAR to render T cells susceptible to HIV infection, at the time this project was 
initiated the published accounts of the original clinical CD4-zeta CAR did not 
address this issue.  In fact, the only source available at that time that even 
mentioned the CD4 CAR facilitating infection was the clinical protocol written by 
Cell Genesys, the company that manufactured the retroviral vector utilized in the 
trial.  A few short sentences stated:  
 
“The theoretical possibility exists that these transduced cells will become 
susceptible to HIV infection, as the virus gains entry into cells using the CD4 
glycoprotein as a receptor.  Consequently, studies were designed to test the 
infectibility of the [CD4-zeta] CD8+ T cells in vitro.  Using two different strains of 
virus (HIV-1 IIIB and JR-CSF) in 7-day cultures, preliminary results have 
detected no evidence of infection in genetically modified cells based on the 
absence of p24gag in the supernatant (data on file, Cell Genesys, Inc.).”   
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In contrast to this report, early in my thesis work it became apparent that 
CD4 CAR expression facilitated infection of CD8 T cells.  At first I concluded the 
opposite, as cell-free virus never resulted in a productive HIV infection, as 
determined by an intracellular Gag signal in the CD4 CAR CD8 T cells that 
increased in frequency over time.  However, once I established a coculture 
system in which CAR-transduced effector cells were diluted down to low levels 
with HIV-infected CD4 T cells, it became apparent that an E:T ratio could be 
reached such that the CAR CD8 T cells became infected.  This observation 
promoted an entire extension of the project, protecting CAR T cells, which was 
discussed in Chapter 3.  Moreover, we discovered that the mechanism by which 
these CAR CD8 T cells become infected is fairly complex and difficult to tease 
apart in vitro, as we could not prevent infection using either Δ32 CD8 T cells or 
scFv CAR T cells.  Whether this is a byproduct of our in vitro coculture assays, or 
an inevitable consequence of CAR T cells fusing their membranes with HIV-
infected target cells during killing remains to be determined.   
 
Protecting CAR T cells with CCR5 ZFNs may be beneficial, but more data is 
required to conclude consistent benefits.  In general, utilizing CCR5 ZFNs to 
protect our CD4 CAR CD8 T cells did not drastically alter the outcomes in terms 
of cell counts or viral control.  While pre-treating CD8 T cells with CCR5 ZFNs 
resulted in significantly reduced viral loads for the MMLV CD4-zeta clinical trial 
CAR in the HIV prevention model, similar treatment had no benefit for the BBz or 
28z CAR T cells in either model.  In the HIV treatment model the 28z cohort 
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succumbed to high viral loads, so based on the prevention model results we 
could predict to see a window of opportunity in which we would detect a benefit 
from ZFNs, yet no such benefit was seen.  Long et al. reported higher levels of 
exhaustion in CAR T cells containing both CD28 and CD3-zeta costimulatory 
domains, compared to those containing solely CD3-zeta (58).  It is possible that 
negative in vivo effects of utilizing a 28z CAR mitigated the antiviral effects of 
CCR5 ZFNs, since protecting dysfunctional CAR T cells would not promote 
better control over HIV. 
ZFN treatment also did not enhance CAR CD8 T cell counts in the HIV 
prevention model, but did enhance both BBz and 28z CAR CD8 T cell counts in 
the HIV treatment model, albeit to a nonsignificant extent.  Importantly, we do not 
have conclusive evidence whether ZFN modified CAR T cells truly enriched in 
their disrupted alleles over time, or simply did not succumb to the negative 
selection effects that occurred in the absence of HIV.  A longer term experiment 
where CD4 T cells could be replenished, such as a BLT mouse model, may be 
beneficial in answering if the trends we saw in our two mouse experiments will be 
consistent over a longer period of time and in the absence of overt GVHD. 
 
Future directions 
 
The greatly augmented control we have achieved through re-engineering 
the clinical trial CD4-zeta CAR provides much optimism to revisit the clinic and 
examine to what extent the improved CAR can provide durable control over HIV 
153 
 
in patients.  However, many unanswered questions remain; we have only 
breached the tip of the iceberg in terms of analyzing the functionality of CD4 CAR 
T cells in vivo.  While we chose to use an NSG hu-T cell mouse model for its 
simplicity and the ability to inject fully human CD4 T cells that were grown using a 
similar method to the CAR T cell trials, we also acknowledge that this model has 
many drawbacks for modeling HIV.  In particular, it is a short-term model due to 
the inability to regenerate new CD4 T cells once depleted by HIV or on the 
contrary, if a therapy works then the human T cells expand rapidly and result in 
the onset of GVHD.   
Moving forward, better animal models of long-term CAR T cell trafficking, 
survival, and control could be developed.  We favor the use of the bone marrow-
liver-thymus (BLT) mouse model or the simian/human immunodeficiency virus 
(SHIV) non-human primate (NHP) model.  In the BLT mouse model, the T cell 
responses are surprisingly recapitulative of the human T cell response to HIV 
(224), and Colby Maldini in the Riley lab has shown that BLT-derived splenic 
CD8 and CD4 T cells can be activated and transduced to express the CD4 CAR, 
and then exhibit functionality in terms of cytokine production and control over HIV 
in vitro (unpublished data).  Recently, George Shaw’s lab improved SHIV design 
to generate a virus capable of replicating to high titer in rhesus macaques (225).  
SHIV models would allow us to utilize our human CD4-based CAR in long-term 
NHP studies, ideal for studying HIV functional cure therapies in the absence of 
GVHD.  Another benefit of using NHP is the ability to assess anti-CAR antibody 
development in immune-competent animals over a number of years, which could 
154 
 
arise in response to a foreign peptide created by fusing the CD4 extracellular 
domain to the CD8α extracellular hinge.    
These improved animal models would allow us to analyze a variety of 
critical parameters pertaining to CAR T cell phenotype and efficacy.  To begin, 
we did not analyze CAR T cell trafficking in the NSG mice beyond peripheral 
blood and spleen.  It will be informative to follow CAR T cell trafficking patterns 
by analyzing numerous lymphoid and non-lymphoid tissues.  It has been 
demonstrated in HIV patients that CD8 T cells fail to enter lymphoid follicles or 
fail to upregulate CTL function (226, 227).  Whether or not CD4 CAR T cells can 
traffic to lymphoid follicles or whether that is required for suppression of the virus 
in vivo remains unknown.  New technologies, including whole-body immunoPET 
scanning, could provide a non-invasive method for tracking CAR T cell therapy in 
NHPs over time (228).   
Sustained cytotoxic effector functions are critical for suppressing HIV in 
the absence of ART, as it is unlikely CAR T cells will be able to rid the body of 
every single cell harboring replication-competent virus.  Thomas Burn, a previous 
rotation student in the Riley lab saw both upregulation of PD-1 and sustained 
expression on PD-1 in CD4 CAR-transduced CD8 T cells, but not in CD8 T cells 
expressing the PG9 scFv based CAR (unpublished data).  A more 
comprehensive analysis of the in vitro and in vivo phenotypes of CAR T cells, 
including exhaustion and activation markers and memory cell phenotyping is 
currently lacking.  Nevertheless, the survival advantage we see with our CD4 
BBz CAR T cells is consistent with the recent report describing the central 
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memory phenotype ascribed to 4-1BB expression in CAR T cells and the effector 
memory phenotype ascribed to CD28-containing CAR T cells (229).  In addition 
to phenotyping with surface antibodies or measuring intracellular proteins with 
western blots, we could simultaneously perform RNA expression analysis on 
CD4 CAR transduced T cells after transduction in vitro and after long-term 
survival in vivo.  We could use the findings of these studies to inform future 
therapeutic models such as determining if checkpoint blockade could augment 
CD4 CAR T cell function.   
As demonstrated in Chapter 4, modeling the HIV reservoir in vitro is very 
challenging, and BLT and SIV/SHIV models could greatly inform our 
understanding of CD4 CAR T cell treatment in the context of ART and in 
preventing HIV rebound once ART has been removed (189, 230).  Moreover 
these animal models could allow us to determine whether virus escape from the 
CD4 CAR is possible over a period of several months or years.  We hypothesize 
that escape from CD4 binding would impose a detrimental fitness cost to the 
virus, as CD4-independent viruses have previously been described as 
neutralization sensitive and intrinsically unstable (231).  Nevertheless a few 
reports of CD4-independent isolates of HIV have been described (232, 233).  
Moreover, the pressure exerted by CTLs expressing a CD4-based CAR may 
force virus evolution in a manner very different than natural HIV infection.  Long-
term animal experiments could track the evolution of HIV quasispecies over time 
in the presence of CAR T cells and could test for escape over several years.     
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As mentioned throughout this thesis, an area that requires much more 
work regards protecting CAR-transduced T cells.  At the present time, it is 
unclear to what extent protecting CAR T cells is beneficial in vivo and what 
protection method or methods are best.  Since both Δ32 and scFv-based CAR 
CD8 T cells were susceptible to HIV infection, it appears that either CAR T cells 
can exogenously uptake the necessary cell entry components or that infection via 
an HIV-specific CAR may not require the traditional receptor plus coreceptor 
infection pathway.  Along these lines, Aucher et al. reported in vitro CD4 uptake 
by CD8 T cells from HIV-infected patients, which could then induce syncytia 
formation in culture (234).  Moreover, the immunologic and virologic synapse 
created by CAR-transduced CTLs fusing with their targets may look very different 
than the host membranes that HIV typically encounters upon natural infection.  A 
recent CRISPR screen identified proteins besides CD4 and CCR5, including cell 
adhesion molecules, important for HIV cell-cell transmission (235).  One could 
imagine that in the context of high affinity CAR binding plus the contributions of 
the immunological synapse, the strict requirement for coreceptor, or even CD4, 
might be bypassed.      
Finally, the observed negative selection of CCR5-disrupted cells in our 
mouse model warrants further investigation to determine if this was a fluke 
observation, specific to the NSG mouse model we used, or a true phenotypic 
consequence of losing CCR5 (or CXCR4, as described below).  As mentioned 
previously, Perez et al. had a decreased proportion of CCR5 disrupted alleles in 
the uninfected mice at the endpoint of their mouse experiment (83).  Similar to 
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our observations that CCR5 disruption decreased to almost 0% in our uninfected 
animals, a report using CXCR4-directed ZFNs in CD4 T cells saw the CXCR4 
disruption drop from 16% to almost 0% in uninfected NSG mice (138).  In direct 
contrast, two additional reports using CXCR4-targeting ZFNs, one of which 
simultaneously edited CD4 T cells with ZFNs directed at CCR5, did not see the 
proportion of disrupted CXCR4 or CCR5 alleles drop in the uninfected mice 
relative to the infusion product (137, 139).  No obvious methodological 
differences exist in mouse strain or experimental timeline, and all other reports 
(besides ours) utilized an Ad5/F35 vector to introduce the ZFNs.  Moreover, the 
same CCR5 ZFN proteins used in the Perez study (which saw a decrease in 
CCR5 disrupted alleles) were utilized in the Didigu study (which saw stable levels 
of CCR5 disruption in the context of no HIV and dual ZFN treatment), so this 
effect is not specific to different ZFN designs.  Natural deletion of CCR5 surface 
expression by the Δ32 mutation is not similarly detrimental in humans, as T cells 
can be readily isolated from people with this mutation.  Nevertheless, differential 
gene expression has been found to be associated with the Δ32 mutation (236).  
Moreover, the Δ32 mutation uniformly occurs in these people, so they don’t have 
the potential for competition between WT and Δ32 cells that could result from 
partial CCR5 deletion with ZFNs.  In summary, further animal models applying 
the coreceptor-targeting ZFNs will be required to conclusively determine if the 
edited cells survive and are phenotypically normal.  
Since ART can almost completely suppress HIV replication in the majority 
of patients, the bar is set high for explorative therapies including CAR T cells.  
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Unless these new therapies can durably suppress HIV for months or years in the 
absence of ART, their development will not progress beyond small pilot studies in 
humans.  While major strides have been made in the field of T cell engineering 
for adoptive therapy, including demonstrations of safety and feasibility, no clinical 
trial has resulted in durable and consistent control over HIV-replication in the 
absence of ART.  Combinatorial approaches that produce HIV-resistant cells and 
simultaneously augment HIV-specific CD4 and CD8 T cell immunity will likely 
have greater effects on long-term control.  Identifying what T cell subsets afford 
the greatest proliferative capacity and transgene expression over time in vivo, 
such as naïve or stem cell memory phenotypes, may similarly augment 
suppression of HIV.  The data presented throughout this thesis provide evidence 
that CD4-based CARs could play an important role in redirecting T cells, 
improving immune-mediated control, and achieving a functional cure for HIV.  
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